_MEMBER_att_D_no_prior_0 - 1.8-2.2,_MEMBER_att_D_no_prior_0 - 4.5-5.5,_MEMBER_att_D_no_prior_0 - 9.0-11.0,_LogP_att_D_no_prior_0 - 1.8-2.2,_LogP_att_D_no_prior_0 - 4.5-5.5,_LogP_att_D_no_prior_0 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-2.6,-2.6,-4.9,GO:0051216,cartilage development,M111,3,0
1,1,1,-14,-5.9,-9,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-2.7,-2.3,-5.9,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-3.6,-2.2,-2,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M111,3,0
1,1,1,-2.4,-2.3,-2.4,GO:0009615,response to virus,M111,3,0
1,1,1,-4.3,-3.1,-2.1,hsa05161,Hepatitis B,M111,3,0
1,1,1,-18,-8.3,-4.1,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-4.3,-11,-2.4,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-2.6,-3.5,-2.7,R-HSA-6798695,Neutrophil degranulation,M111,3,0
1,1,1,-12,-4.5,-2.2,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-4.3,-3.9,-3.6,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-4.1,-5.1,-3.7,GO:0001501,skeletal system development,M111,3,0
1,1,1,-8.4,-4.8,-2.8,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-23,-10,-7,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-16,-9.2,-2.6,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-11,-3.8,-2.1,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-5.5,-2.6,-3.6,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-5.1,-4.7,-2.4,hsa05170,Human immunodeficiency virus 1 infection,M111,3,0
1,1,1,-6.4,-2.5,-2,GO:0045089,positive regulation of innate immune response,M111,3,0
1,1,1,-6,-5.4,-2.1,hsa05166,Human T-cell leukemia virus 1 infection,M111,3,0
1,1,1,-4.2,-2.8,-2.2,WP4666,Hepatitis B infection,M111,3,0
1,1,1,-3.3,-2.7,-4.1,GO:0061448,connective tissue development,M111,3,0
1,1,1,-14,-8,-2.6,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-5.1,-4,-2.5,GO:0031349,positive regulation of defense response,M111,3,0
1,1,1,-13,-8.6,-2.6,GO:0001775,cell activation,M111,3,0
1,1,1,-5.3,-2.3,-3.1,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-3.5,-3,-2,R-HSA-8939211,ESR-mediated signaling,M111,3,0
1,1,1,-14,-7.2,-2.6,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-5.6,-2.1,-2.9,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-9.4,-4,-3.2,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,0,-3.8,-3.7,0,WP4659,Gastrin signaling pathway,M110,2,0
1,1,0,-2.3,-2.3,0,GO:0002285,lymphocyte activation involved in immune response,M110,2,0
1,1,0,-2,-4.4,0,M252,PID IL8 CXCR1 PATHWAY,M110,2,0
1,1,0,-3,-3.8,0,WP2018,RANKL RANK signaling pathway,M110,2,0
1,1,0,-2.5,-2.3,0,GO:1903530,regulation of secretion by cell,M110,2,0
1,1,0,-7.4,-5.6,0,GO:0002429,immune response-activating cell surface receptor signaling pathway,M110,2,0
1,1,0,-8.3,-5.8,0,GO:1902107,positive regulation of leukocyte differentiation,M110,2,0
1,1,0,-3.5,-2.8,0,R-HSA-166520,Signaling by NTRKs,M110,2,0
1,1,0,-2.4,-2.2,0,GO:0030100,regulation of endocytosis,M110,2,0
1,1,0,-7.3,-3.3,0,GO:0002761,regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-8.3,-5.3,0,M167,PID AP1 PATHWAY,M110,2,0
1,1,0,-2.3,-2.7,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,1,0,-7.3,-2.5,0,GO:0009617,response to bacterium,M110,2,0
1,1,0,-3.9,-2.7,0,GO:2000630,positive regulation of miRNA metabolic process,M110,2,0
1,1,0,-8.2,-4.4,0,M183,PID IL6 7 PATHWAY,M110,2,0
1,1,0,-7.2,-5,0,GO:0051251,positive regulation of lymphocyte activation,M110,2,0
1,1,0,-4.5,-5.6,0,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M110,2,0
1,0,1,-2.2,0,-3.2,GO:0072189,ureter development,M101,2,0
1,1,0,-3.5,-4.2,0,R-HSA-195721,Signaling by WNT,M110,2,0
1,1,0,-2.7,-2.1,0,WP673,ErbB signaling pathway,M110,2,0
1,1,0,-2.1,-3.2,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-3.2,-2.8,0,GO:0050853,B cell receptor signaling pathway,M110,2,0
1,1,0,-4.5,-3.4,0,GO:0051345,positive regulation of hydrolase activity,M110,2,0
1,1,0,-2.4,-2.8,0,hsa05225,Hepatocellular carcinoma,M110,2,0
1,1,0,-5.5,-4.4,0,WP5098,T cell activation SARS CoV 2,M110,2,0
1,1,0,-6.8,-5.8,0,M235,PID TCR CALCIUM PATHWAY,M110,2,0
1,1,0,-9.5,-8,0,GO:1902105,regulation of leukocyte differentiation,M110,2,0
1,1,0,-2.6,-2.3,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,1,0,-2.4,-2.2,0,GO:0002702,positive regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M110,2,0
1,1,0,-2.1,-2.2,0,GO:0044092,negative regulation of molecular function,M110,2,0
1,1,0,-4.9,-3.7,0,hsa05203,Viral carcinogenesis,M110,2,0
1,1,0,-2.6,-3.9,0,M223,PID BETA CATENIN NUC PATHWAY,M110,2,0
1,1,0,-6.8,-6.8,0,hsa04660,T cell receptor signaling pathway,M110,2,0
1,1,0,-3.5,-2.9,0,WP2355,Corticotropin releasing hormone signaling pathway,M110,2,0
1,1,0,-7.4,-2.5,0,GO:0071396,cellular response to lipid,M110,2,0
1,1,0,-3.3,-3.5,0,WP2882,Nuclear receptors meta pathway,M110,2,0
1,1,0,-3,-2.2,0,GO:0002704,negative regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-11,-4.5,0,GO:0010720,positive regulation of cell development,M110,2,0
1,1,0,-2.2,-7,0,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M110,2,0
1,1,0,-6.2,-3.1,0,GO:0140747,regulation of ncRNA transcription,M110,2,0
1,1,0,-7.3,-4,0,M60,PID NFAT TFPATHWAY,M110,2,0
1,1,0,-2.8,-2.9,0,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M110,2,0
1,1,0,-2.7,-4,0,hsa05210,Colorectal cancer,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0001503,ossification,M110,2,0
1,1,0,-2.6,-3.2,0,hsa04062,Chemokine signaling pathway,M110,2,0
0,1,1,0,-2.5,-2.1,GO:0051100,negative regulation of binding,M011,2,0
1,1,0,-3.7,-2.3,0,M28,PID IL4 2PATHWAY,M110,2,0
1,1,0,-2.9,-2.3,0,WP5094,Orexin receptor pathway,M110,2,0
1,1,0,-3.1,-2.5,0,R-HSA-2172127,DAP12 interactions,M110,2,0
1,1,0,-2.6,-3.9,0,GO:0070665,positive regulation of leukocyte proliferation,M110,2,0
1,1,0,-2.2,-3.5,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M110,2,0
1,1,0,-5.1,-2.4,0,GO:0002218,activation of innate immune response,M110,2,0
1,1,0,-5.6,-2.5,0,GO:0032943,mononuclear cell proliferation,M110,2,0
1,1,0,-3.8,-2.7,0,GO:0042098,T cell proliferation,M110,2,0
1,1,0,-2.4,-3.5,0,hsa05132,Salmonella infection,M110,2,0
1,1,0,-5.1,-4.2,0,WP399,Wnt signaling pathway and pluripotency,M110,2,0
1,1,0,-4.6,-5.2,0,R-HSA-2871796,FCERI mediated MAPK activation,M110,2,0
1,1,0,-3.8,-3,0,R-HSA-5621481,C-type lectin receptors (CLRs),M110,2,0
1,1,0,-3.8,-2.3,0,R-HSA-202403,TCR signaling,M110,2,0
1,1,0,-3.4,-3.1,0,R-HSA-9607240,FLT3 Signaling,M110,2,0
1,1,0,-3.4,-2.3,0,GO:0002366,leukocyte activation involved in immune response,M110,2,0
1,1,0,-2.2,-3.8,0,WP4223,Ras signaling,M110,2,0
1,1,0,-2.5,-5.2,0,hsa04218,Cellular senescence,M110,2,0
1,1,0,-2.4,-2.1,0,R-HSA-451927,Interleukin-2 family signaling,M110,2,0
1,1,0,-2,-3.5,0,hsa04912,GnRH signaling pathway,M110,2,0
1,0,1,-5,0,-2.1,GO:0048872,homeostasis of number of cells,M101,2,0
1,1,0,-2.2,-3,0,M5493,WNT SIGNALING,M110,2,0
1,1,0,-6.6,-8.8,0,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M110,2,0
1,1,0,-2,-4.4,0,M234,PID IL2 STAT5 PATHWAY,M110,2,0
1,1,0,-2.9,-2,0,GO:0010562,positive regulation of phosphorus metabolic process,M110,2,0
1,1,0,-3.2,-2,0,GO:0045807,positive regulation of endocytosis,M110,2,0
1,1,0,-10,-6.9,0,GO:0051249,regulation of lymphocyte activation,M110,2,0
1,1,0,-3.7,-5.6,0,R-HSA-9824443,Parasitic Infection Pathways,M110,2,0
1,1,0,-2.5,-3.6,0,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M110,2,0
1,1,0,-2.5,-2.5,0,hsa05134,Legionellosis,M110,2,0
1,1,0,-2.5,-2.2,0,WP4136,Fibrin complement receptor 3 signaling pathway,M110,2,0
1,1,0,-3.7,-3.7,0,R-HSA-4086398,Ca2+ pathway,M110,2,0
1,1,0,-2.7,-3.8,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M110,2,0
1,1,0,-2.2,-2.5,0,GO:0006984,ER-nucleus signaling pathway,M110,2,0
1,1,0,-2.9,-2.6,0,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M110,2,0
1,1,0,-4.2,-3.8,0,GO:0030183,B cell differentiation,M110,2,0
1,0,1,-2,0,-3.1,WP5224,2q37 copy number variation syndrome,M101,2,0
1,1,0,-2.2,-2.5,0,GO:0070670,response to interleukin-4,M110,2,0
1,1,0,-2.6,-2.5,0,GO:0050671,positive regulation of lymphocyte proliferation,M110,2,0
1,1,0,-8.9,-4.9,0,GO:0002253,activation of immune response,M110,2,0
1,1,0,-2,-2.6,0,hsa04657,IL-17 signaling pathway,M110,2,0
1,1,0,-2.8,-2.3,0,GO:0002698,negative regulation of immune effector process,M110,2,0
1,1,0,-4.2,-2.8,0,GO:0009725,response to hormone,M110,2,0
1,1,0,-3.8,-2,0,R-HSA-9679191,Potential therapeutics for SARS,M110,2,0
1,1,0,-2.6,-2.8,0,WP313,Hepatocyte growth factor receptor signaling,M110,2,0
1,1,0,-4.4,-3.3,0,M206,PID PDGFRA PATHWAY,M110,2,0
1,1,0,-8.5,-8.4,0,GO:1903037,regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-2.8,-2.2,0,GO:1902075,cellular response to salt,M110,2,0
1,1,0,-2.9,-5.6,0,R-HSA-9012999,RHO GTPase cycle,M110,2,0
1,1,0,-2,-2.6,0,GO:0046640,regulation of alpha-beta T cell proliferation,M110,2,0
1,1,0,-2.1,-4,0,GO:1901652,response to peptide,M110,2,0
1,0,1,-2.5,0,-2,hsa04935,"Growth hormone synthesis, secretion and action",M101,2,0
1,1,0,-3.8,-2.4,0,M65,PID FRA PATHWAY,M110,2,0
1,1,0,-2.6,-3.4,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M110,2,0
1,1,0,-3.1,-2,0,R-HSA-9031628,NGF-stimulated transcription,M110,2,0
1,1,0,-5.4,-3.5,0,GO:0070663,regulation of leukocyte proliferation,M110,2,0
0,1,1,0,-2.5,-2.6,M285,PID HNF3A PATHWAY,M011,2,0
1,1,0,-2.4,-3,0,GO:0043547,positive regulation of GTPase activity,M110,2,0
1,1,0,-6.1,-2.9,0,GO:0002250,adaptive immune response,M110,2,0
1,1,0,-2.9,-2.1,0,hsa04630,JAK-STAT signaling pathway,M110,2,0
1,1,0,-4.9,-3.1,0,GO:0070661,leukocyte proliferation,M110,2,0
1,1,0,-2.2,-6,0,hsa04664,Fc epsilon RI signaling pathway,M110,2,0
1,1,0,-6.3,-4.4,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,1,0,-5.3,-4.4,0,hsa04659,Th17 cell differentiation,M110,2,0
1,1,0,-3.4,-2.3,0,GO:0002263,cell activation involved in immune response,M110,2,0
1,1,0,-3.5,-4.3,0,GO:0006468,protein phosphorylation,M110,2,0
1,0,1,-2.6,0,-3.4,GO:0035855,megakaryocyte development,M101,2,0
1,1,0,-3.5,-4.1,0,GO:0050777,negative regulation of immune response,M110,2,0
1,1,0,-4,-2.1,0,GO:0031341,regulation of cell killing,M110,2,0
1,1,0,-5,-3,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M110,2,0
1,1,0,-5.6,-3.9,0,hsa04658,Th1 and Th2 cell differentiation,M110,2,0
1,1,0,-5.1,-2.9,0,GO:0071559,response to transforming growth factor beta,M110,2,0
1,1,0,-5.1,-4,0,GO:0002703,regulation of leukocyte mediated immunity,M110,2,0
0,1,1,0,-2.5,-4.2,R-HSA-73980,RNA Polymerase III Transcription Termination,M011,2,0
1,1,0,-2.2,-2.5,0,WP127,IL 5 signaling pathway,M110,2,0
1,1,0,-5.2,-6.4,0,GO:0050727,regulation of inflammatory response,M110,2,0
1,1,0,-4,-5.5,0,M186,PID PDGFRB PATHWAY,M110,2,0
1,1,0,-4.1,-2.2,0,GO:0009611,response to wounding,M110,2,0
1,1,0,-2.7,-3.8,0,GO:0032655,regulation of interleukin-12 production,M110,2,0
1,1,0,-4.4,-7.3,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-4.8,-6.9,0,WP5293,Acute myeloid leukemia,M110,2,0
1,1,0,-2.9,-4.2,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M110,2,0
1,1,0,-2.9,-2,0,GO:0045937,positive regulation of phosphate metabolic process,M110,2,0
1,1,0,-2.7,-2.5,0,GO:0046629,gamma-delta T cell activation,M110,2,0
1,1,0,-4.8,-2.8,0,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M110,2,0
1,1,0,-4,-8.9,0,M10,PID BCR 5PATHWAY,M110,2,0
1,1,0,-3.7,-2.3,0,M99,PID TXA2PATHWAY,M110,2,0
1,1,0,-3.7,-8.2,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,1,0,-4.8,-2.8,0,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M110,2,0
1,1,0,-3.5,-3.2,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M110,2,0
1,1,0,-3.1,-2.3,0,GO:0071496,cellular response to external stimulus,M110,2,0
1,1,0,-3.9,-3,0,GO:0034341,response to type II interferon,M110,2,0
1,1,0,-3.8,-2.9,0,GO:0030851,granulocyte differentiation,M110,2,0
1,1,0,-2.5,-3.3,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-8.3,-4.8,0,GO:0045639,positive regulation of myeloid cell differentiation,M110,2,0
1,0,1,-2.7,0,-3,GO:0030219,megakaryocyte differentiation,M101,2,0
1,1,0,-3,-3.1,0,GO:0009991,response to extracellular stimulus,M110,2,0
1,1,0,-5.3,-2.1,0,GO:0001701,in utero embryonic development,M110,2,0
1,1,0,-6.3,-4.5,0,GO:0045087,innate immune response,M110,2,0
1,1,0,-8.6,-5.2,0,GO:0001819,positive regulation of cytokine production,M110,2,0
1,1,0,-2.6,-3.4,0,WP5130,Th17 cell differentiation pathway,M110,2,0
1,1,0,-2.8,-3.3,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,1,0,-4,-3.1,0,GO:0001892,embryonic placenta development,M110,2,0
1,1,0,-2.4,-2.1,0,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M110,2,0
1,1,0,-4.1,-2.1,0,GO:0022408,negative regulation of cell-cell adhesion,M110,2,0
1,1,0,-4.7,-4.6,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-3,-4,0,GO:0050864,regulation of B cell activation,M110,2,0
1,1,0,-7.2,-6,0,GO:0002696,positive regulation of leukocyte activation,M110,2,0
1,1,0,-5.2,-3,0,GO:2000628,regulation of miRNA metabolic process,M110,2,0
1,1,0,-2.8,-8.1,0,M7,PID FCER1 PATHWAY,M110,2,0
1,1,0,-5.6,-2.5,0,GO:0046651,lymphocyte proliferation,M110,2,0
1,1,0,-3.9,-4.8,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,1,0,-7.9,-5.9,0,GO:0022407,regulation of cell-cell adhesion,M110,2,0
1,1,0,-3,-2.8,0,GO:0043087,regulation of GTPase activity,M110,2,0
1,1,0,-3.4,-3.8,0,GO:0046637,regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-4.9,-2.9,0,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M110,2,0
0,1,1,0,-2.8,-2.4,R-HSA-9679506,SARS-CoV Infections,M011,2,0
1,1,0,-3.2,-2.3,0,WP4262,Breast cancer pathway,M110,2,0
1,1,0,-2.5,-2.9,0,GO:0032946,positive regulation of mononuclear cell proliferation,M110,2,0
1,1,0,-2.5,-5,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M110,2,0
1,1,0,-5.2,-3,0,WP2857,Mesodermal commitment pathway,M110,2,0
1,1,0,-7.1,-4.9,0,GO:0006954,inflammatory response,M110,2,0
1,1,0,-3.1,-4,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-2.9,-2.6,0,R-HSA-9664433,Leishmania parasite growth and survival,M110,2,0
1,1,0,-2.9,-4.1,0,GO:0032675,regulation of interleukin-6 production,M110,2,0
1,1,0,-4,-3.5,0,WP3640,Imatinib and chronic myeloid leukemia,M110,2,0
1,1,0,-4.5,-4,0,WP2374,Oncostatin M signaling pathway,M110,2,0
1,1,0,-5.4,-4.6,0,GO:0042113,B cell activation,M110,2,0
1,1,0,-5.1,-4.2,0,R-HSA-168898,Toll-like Receptor Cascades,M110,2,0
1,1,0,-2.4,-2.4,0,GO:0033077,T cell differentiation in thymus,M110,2,0
1,1,0,-13,-9.3,0,GO:1903706,regulation of hemopoiesis,M110,2,0
1,1,0,-2.7,-2.5,0,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-2.4,-2.6,0,M12,PID RHOA PATHWAY,M110,2,0
1,1,0,-3.1,-3.3,0,M255,PID HIF1 TFPATHWAY,M110,2,0
1,1,0,-3.2,-4.4,0,GO:0032870,cellular response to hormone stimulus,M110,2,0
1,1,0,-4.1,-4.5,0,GO:2000377,regulation of reactive oxygen species metabolic process,M110,2,0
1,0,1,-3.6,0,-3.8,GO:0061351,neural precursor cell proliferation,M101,2,0
1,1,0,-2.5,-3.1,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M110,2,0
1,1,0,-2.8,-2.4,0,GO:2000106,regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-6.6,-4,0,R-HSA-1280218,Adaptive Immune System,M110,2,0
1,1,0,-5.3,-2,0,M124,PID CXCR4 PATHWAY,M110,2,0
1,1,0,-3.2,-3.3,0,hsa05169,Epstein-Barr virus infection,M110,2,0
1,1,0,-4.7,-6,0,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M110,2,0
1,1,0,-2.1,-2.4,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M110,2,0
1,1,0,-11,-5.6,0,GO:0042110,T cell activation,M110,2,0
1,0,1,-5.7,0,-2.4,GO:0002262,myeloid cell homeostasis,M101,2,0
1,1,0,-2.9,-3.9,0,hsa04936,Alcoholic liver disease,M110,2,0
1,1,0,-5,-2.9,0,GO:0070848,response to growth factor,M110,2,0
1,0,1,-7.6,0,-2.1,GO:0045165,cell fate commitment,M101,2,0
1,0,1,-2.7,0,-2.4,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M101,2,0
1,1,0,-6.4,-3.6,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-3.6,-2.5,0,GO:0050868,negative regulation of T cell activation,M110,2,0
1,0,1,-2.6,0,-2,GO:0050680,negative regulation of epithelial cell proliferation,M101,2,0
1,1,0,-4.5,-2.7,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M110,2,0
1,1,0,-2.4,-2.8,0,R-HSA-201681,TCF dependent signaling in response to WNT,M110,2,0
1,1,0,-5.6,-3.1,0,GO:0006909,phagocytosis,M110,2,0
1,1,0,-3.4,-3,0,GO:0051336,regulation of hydrolase activity,M110,2,0
1,1,0,-5.4,-2.2,0,GO:0046631,alpha-beta T cell activation,M110,2,0
1,1,0,-4.6,-5.8,0,WP286,IL 3 signaling pathway,M110,2,0
1,1,0,-7,-10,0,WP23,B cell receptor signaling pathway,M110,2,0
1,1,0,-6.1,-2.8,0,GO:0051250,negative regulation of lymphocyte activation,M110,2,0
1,1,0,-8.5,-4.5,0,GO:0002764,immune response-regulating signaling pathway,M110,2,0
1,1,0,-4.9,-7,0,hsa05221,Acute myeloid leukemia,M110,2,0
1,1,0,-5,-5.1,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M110,2,0
1,1,0,-3.3,-3.7,0,M22,PID GMCSF PATHWAY,M110,2,0
1,1,0,-3.6,-3.4,0,hsa04650,Natural killer cell mediated cytotoxicity,M110,2,0
1,1,0,-3.9,-3.6,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-4.1,-3,0,GO:0002274,myeloid leukocyte activation,M110,2,0
1,1,0,-3.9,-6,0,M8626,SIG BCR SIGNALING PATHWAY,M110,2,0
1,1,0,-4.5,-2.1,0,GO:0042129,regulation of T cell proliferation,M110,2,0
1,1,0,-2.7,-2.1,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M110,2,0
1,1,0,-2.1,-4.1,0,R-HSA-194315,Signaling by Rho GTPases,M110,2,0
1,1,0,-6.4,-7.1,0,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-3.3,-2.6,0,WP4585,Cancer immunotherapy by PD 1 blockade,M110,2,0
1,1,0,-4.2,-3.2,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,1,0,-3.8,-3.6,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M110,2,0
1,1,0,-3.1,-3.8,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M110,2,0
1,1,0,-2,-3.1,0,GO:0046643,regulation of gamma-delta T cell activation,M110,2,0
1,1,0,-5,-4.9,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,1,0,-3.3,-3.9,0,GO:0002819,regulation of adaptive immune response,M110,2,0
1,1,0,-9.1,-11,0,R-HSA-1280215,Cytokine Signaling in Immune system,M110,2,0
1,0,1,-4.3,0,-4.9,GO:0061515,myeloid cell development,M101,2,0
1,1,0,-4.1,-6.5,0,GO:0019221,cytokine-mediated signaling pathway,M110,2,0
1,1,0,-3.5,-2.2,0,GO:0006959,humoral immune response,M110,2,0
1,1,0,-7.3,-2.3,0,GO:0045088,regulation of innate immune response,M110,2,0
1,1,0,-4.3,-5.2,0,GO:0032103,positive regulation of response to external stimulus,M110,2,0
1,1,0,-11,-7.3,0,GO:0050778,positive regulation of immune response,M110,2,0
1,1,0,-10,-7.8,0,GO:0002694,regulation of leukocyte activation,M110,2,0
1,1,0,-3.5,-2.2,0,GO:0045646,regulation of erythrocyte differentiation,M110,2,0
1,1,0,-2.5,-2.7,0,GO:2000107,negative regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-3.6,-3.4,0,GO:0051090,regulation of DNA-binding transcription factor activity,M110,2,0
1,1,0,-2.2,-4,0,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M110,2,0
1,1,0,-4.5,-8.5,0,hsa04662,B cell receptor signaling pathway,M110,2,0
1,1,0,-2.2,-3.3,0,GO:0045586,regulation of gamma-delta T cell differentiation,M110,2,0
1,1,0,-5.7,-6.2,0,GO:0022409,positive regulation of cell-cell adhesion,M110,2,0
1,1,0,-4.3,-5.1,0,GO:0050728,negative regulation of inflammatory response,M110,2,0
1,1,0,-7.1,-5.3,0,WP69,T cell receptor signaling pathway,M110,2,0
1,0,1,-3.2,0,-3.1,GO:0072089,stem cell proliferation,M101,2,0
1,1,0,-8,-7.1,0,GO:0050863,regulation of T cell activation,M110,2,0
1,1,0,-4.2,-2.4,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,0,1,-3.5,0,-3,R-HSA-8878171,Transcriptional regulation by RUNX1,M101,2,0
1,1,0,-2.9,-4.5,0,M122,PID IL2 1PATHWAY,M110,2,0
1,1,0,-2.7,-2.5,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M110,2,0
1,1,0,-2,-2,0,GO:0006111,regulation of gluconeogenesis,M110,2,0
1,1,0,-4.6,-4.2,0,GO:0045785,positive regulation of cell adhesion,M110,2,0
1,1,0,-2.7,-2.6,0,hsa05216,Thyroid cancer,M110,2,0
1,1,0,-4.3,-4.2,0,WP366,TGF beta signaling pathway,M110,2,0
1,1,0,-4.4,-3.1,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M110,2,0
1,0,1,-4.9,0,-3.3,M2,PID SMAD2 3NUCLEAR PATHWAY,M101,2,0
1,1,0,-2.9,-2.6,0,WP2324,AGE RAGE pathway,M110,2,0
1,1,0,-3.2,-4.8,0,hsa05135,Yersinia infection,M110,2,0
1,1,0,-3.6,-2.3,0,M88,PID CD8 TCR PATHWAY,M110,2,0
1,1,0,-2.3,-2.1,0,GO:0019722,calcium-mediated signaling,M110,2,0
1,1,0,-3.8,-2.5,0,GO:0071363,cellular response to growth factor stimulus,M110,2,0
1,1,0,-4.4,-3.3,0,hsa04010,MAPK signaling pathway,M110,2,0
1,1,0,-2.9,-3,0,GO:0031668,cellular response to extracellular stimulus,M110,2,0
1,1,0,-11,-2.5,0,GO:0030217,T cell differentiation,M110,2,0
1,1,0,-4.5,-3,0,GO:1902895,positive regulation of miRNA transcription,M110,2,0
1,1,0,-6.1,-2.6,0,GO:0050866,negative regulation of cell activation,M110,2,0
1,1,0,-4,-2.5,0,WP3937,Microglia pathogen phagocytosis pathway,M110,2,0
1,1,0,-3.3,-4.9,0,M17200,SA B CELL RECEPTOR COMPLEXES,M110,2,0
1,1,0,-2.2,-3.5,0,hsa05131,Shigellosis,M110,2,0
1,1,0,-2.5,-2.7,0,R-HSA-9006931,Signaling by Nuclear Receptors,M110,2,0
1,1,0,-5.8,-8.3,0,GO:0045619,regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.3,-2.3,0,GO:0010035,response to inorganic substance,M110,2,0
1,1,0,-3.3,-2.4,0,WP710,DNA damage response only ATM dependent,M110,2,0
1,1,0,-2.8,-3.6,0,GO:0046635,positive regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-2.4,-2.6,0,GO:0071353,cellular response to interleukin-4,M110,2,0
1,1,0,-3.9,-4.3,0,hsa04310,Wnt signaling pathway,M110,2,0
1,1,0,-4.7,-4.6,0,GO:0071417,cellular response to organonitrogen compound,M110,2,0
1,1,0,-2.1,-3.3,0,GO:0016310,phosphorylation,M110,2,0
1,1,0,-4.7,-2.4,0,WP5072,Modulators of TCR signaling and T cell activation,M110,2,0
1,1,0,-3.6,-2.6,0,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M110,2,0
1,1,0,-2.2,-3,0,R-HSA-9027284,Erythropoietin activates RAS,M110,2,0
1,1,0,-4.8,-2.8,0,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M110,2,0
1,1,0,-2.5,-3,0,GO:0051046,regulation of secretion,M110,2,0
1,1,0,-4.1,-2.1,0,WP4844,Influence of laminopathies on Wnt signaling,M110,2,0
1,1,0,-2.9,-2,0,GO:0062197,cellular response to chemical stress,M110,2,0
1,1,0,-4.1,-3.7,0,GO:0050851,antigen receptor-mediated signaling pathway,M110,2,0
1,1,0,-5.6,-2.5,0,M195,PID CMYB PATHWAY,M110,2,0
1,1,0,-4.1,-3.6,0,WP2853,Endoderm differentiation,M110,2,0
1,1,0,-3.5,-3.5,0,hsa04928,"Parathyroid hormone synthesis, secretion and action",M110,2,0
1,1,0,-2.1,-2.9,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0032757,positive regulation of interleukin-8 production,M110,2,0
1,1,0,-7.7,-5.1,0,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M110,2,0
1,1,0,-4.7,-2.9,0,GO:0002252,immune effector process,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M110,2,0
1,1,0,-4.4,-4,0,WP382,MAPK signaling pathway,M110,2,0
1,1,0,-2.7,-2.3,0,WP2526,PDGF pathway,M110,2,0
1,1,0,-3.7,-3.1,0,GO:0045598,regulation of fat cell differentiation,M110,2,0
1,1,0,-2.1,-2.3,0,GO:0002821,positive regulation of adaptive immune response,M110,2,0
1,1,0,-3.9,-4.8,0,WP437,EGF EGFR signaling pathway,M110,2,0
1,1,0,-3.8,-3,0,hsa05142,Chagas disease,M110,2,0
1,1,0,-6.4,-2.4,0,GO:0002831,regulation of response to biotic stimulus,M110,2,0
1,1,0,-8.3,-5.8,0,GO:1903708,positive regulation of hemopoiesis,M110,2,0
1,1,0,-4.8,-4.9,0,GO:0140467,integrated stress response signaling,M110,2,0
1,1,0,-8,-4.4,0,GO:0002683,negative regulation of immune system process,M110,2,0
1,1,0,-4.6,-5.7,0,WP428,Wnt signaling,M110,2,0
1,1,0,-7,-6.2,0,GO:0050867,positive regulation of cell activation,M110,2,0
1,1,0,-3.1,-2.4,0,WP1541,Energy metabolism,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0045061,thymic T cell selection,M110,2,0
1,1,0,-3.1,-3.5,0,WP363,Wnt signaling pathway,M110,2,0
1,1,0,-2.7,-3.6,0,hsa05163,Human cytomegalovirus infection,M110,2,0
1,1,0,-3.3,-2.3,0,hsa05224,Breast cancer,M110,2,0
1,1,0,-4.2,-2.2,0,GO:0050764,regulation of phagocytosis,M110,2,0
1,1,0,-2.5,-2,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-4.3,-2.2,0,GO:0045600,positive regulation of fat cell differentiation,M110,2,0
1,1,0,-4.8,-2.8,0,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M110,2,0
1,1,0,-4.2,-2.8,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M110,2,0
1,1,0,-3.8,-2,0,WP4149,White fat cell differentiation,M110,2,0
1,1,0,-2.2,-3,0,GO:0042492,gamma-delta T cell differentiation,M110,2,0
1,1,0,-3.4,-3.9,0,GO:0032102,negative regulation of response to external stimulus,M110,2,0
1,1,0,-2.4,-2.8,0,GO:0060326,cell chemotaxis,M110,2,0
1,1,0,-6.1,-2.6,0,GO:0002833,positive regulation of response to biotic stimulus,M110,2,0
1,1,0,-2.2,-2.2,0,R-HSA-9671555,Signaling by PDGFR in disease,M110,2,0
1,1,0,-8.3,-5,0,GO:0002757,immune response-activating signaling pathway,M110,2,0
1,1,0,-2,-3.1,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-2.6,-2.8,0,M210,PID IL8 CXCR2 PATHWAY,M110,2,0
1,1,0,-2.8,-4.5,0,hsa05207,Chemical carcinogenesis - receptor activation,M110,2,0
1,1,0,-5.8,-3.2,0,GO:1902893,regulation of miRNA transcription,M110,2,0
1,1,0,-3.4,-3.8,0,hsa05133,Pertussis,M110,2,0
1,0,1,-2.2,0,-2,R-HSA-157118,Signaling by NOTCH,M101,2,0
1,1,0,-2.5,-3.6,0,GO:0046645,positive regulation of gamma-delta T cell activation,M110,2,0
1,1,0,-3.9,-3,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M110,2,0
1,1,0,-3.1,-4,0,CORUM:2695,ETS2-FOS-JUN complex,M110,2,0
1,1,0,-3.6,-2.2,0,GO:0002699,positive regulation of immune effector process,M110,2,0
1,1,0,-5.2,-4.3,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M110,2,0
1,1,0,-5.9,-3,0,GO:0050670,regulation of lymphocyte proliferation,M110,2,0
1,1,0,-2.2,-2.2,0,hsa04390,Hippo signaling pathway,M110,2,0
1,1,0,-5.7,-3.7,0,GO:0001818,negative regulation of cytokine production,M110,2,0
1,1,0,-2.7,-3,0,R-HSA-9018519,Estrogen-dependent gene expression,M110,2,0
1,1,0,-2.5,-2.6,0,GO:0031669,cellular response to nutrient levels,M110,2,0
1,1,0,-4.1,-4.8,0,GO:0046634,regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-7.6,-6.4,0,hsa04380,Osteoclast differentiation,M110,2,0
1,1,0,-6.5,-3.3,0,GO:0002695,negative regulation of leukocyte activation,M110,2,0
1,1,0,-2.7,-5.4,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M110,2,0
1,1,0,-2.6,-6.6,0,R-HSA-912631,Regulation of signaling by CBL,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0006935,chemotaxis,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0045058,T cell selection,M110,2,0
1,1,0,-3.5,-2.9,0,GO:0002700,regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-3,-2,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M110,2,0
1,1,0,-4.7,-3,0,GO:0001890,placenta development,M110,2,0
1,1,0,-2.2,-2.2,0,GO:0042330,taxis,M110,2,0
1,1,0,-2.8,-3.6,0,R-HSA-2559583,Cellular Senescence,M110,2,0
1,1,0,-8.2,-9,0,GO:0071345,cellular response to cytokine stimulus,M110,2,0
1,1,0,-3.6,-3.2,0,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M110,2,0
1,1,0,-3.1,-2,0,hsa04916,Melanogenesis,M110,2,0
1,1,0,-5.7,-2.1,0,GO:0071216,cellular response to biotic stimulus,M110,2,0
1,1,0,-7.3,-4,0,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M110,2,0
1,1,0,-4.8,-4.4,0,GO:1901699,cellular response to nitrogen compound,M110,2,0
1,1,0,-2.2,-3.3,0,GO:0030888,regulation of B cell proliferation,M110,2,0
1,1,0,-3.5,-2.8,0,R-HSA-2424491,DAP12 signaling,M110,2,0
1,1,0,-2.1,-2.4,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M110,2,0
1,1,0,-3.1,-2.9,0,GO:0045596,negative regulation of cell differentiation,M110,2,0
1,1,0,-3.7,-5.6,0,R-HSA-9658195,Leishmania infection,M110,2,0
1,1,0,-2.5,-2.7,0,GO:0031667,response to nutrient levels,M110,2,0
1,1,0,-3.2,-4.6,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M110,2,0
1,1,0,-3.1,-4,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M110,2,0
1,1,0,-5.9,-4.7,0,GO:0050870,positive regulation of T cell activation,M110,2,0
1,1,0,-4,-3.2,0,GO:0032677,regulation of interleukin-8 production,M110,2,0
1,1,0,-5.8,-3.5,0,GO:0032944,regulation of mononuclear cell proliferation,M110,2,0
1,1,0,-5.4,-5,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M110,2,0
1,1,0,-4.9,-2,0,GO:0071219,cellular response to molecule of bacterial origin,M110,2,0
1,1,0,-4,-3.4,0,hsa05215,Prostate cancer,M110,2,0
1,1,0,-9.3,-4.9,0,GO:0002573,myeloid leukocyte differentiation,M110,2,0
1,1,0,-3,-2.8,0,R-HSA-8878159,Transcriptional regulation by RUNX3,M110,2,0
1,1,0,-4.5,-6.1,0,GO:0031348,negative regulation of defense response,M110,2,0
1,1,0,-5.6,-6.2,0,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M110,2,0
1,1,0,-9.3,-7,0,GO:0050865,regulation of cell activation,M110,2,0
1,1,0,-7.5,-12,0,R-HSA-449147,Signaling by Interleukins,M110,2,0
1,1,0,-9.8,-7.4,0,hsa05200,Pathways in cancer,M110,2,0
1,1,0,-2.4,-3.5,0,WP3929,Chemokine signaling pathway,M110,2,0
0,1,0,0,-2.5,0,hsa05211,Renal cell carcinoma,M010,1,0
0,1,0,0,-2.3,0,GO:0030224,monocyte differentiation,M010,1,0
1,0,0,-3.1,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
1,0,0,-2.2,0,0,R-HSA-166786,Creation of C4 and C2 activators,M100,1,0
0,0,1,0,0,-3.1,GO:0035456,response to interferon-beta,M001,1,0
0,1,0,0,-2.3,0,M159,PID AMB2 NEUTROPHILS PATHWAY,M010,1,0
1,0,0,-2.8,0,0,GO:0060438,trachea development,M100,1,0
0,0,1,0,0,-2,GO:0070085,glycosylation,M001,1,0
1,0,0,-2.2,0,0,WP3953,mRNA protein and metabolite inducation pathway by cyclosporin A,M100,1,0
1,0,0,-4.4,0,0,M34,PID TCR PATHWAY,M100,1,0
1,0,0,-3.5,0,0,M279,PID RB 1PATHWAY,M100,1,0
0,1,0,0,-2.6,0,hsa04340,Hedgehog signaling pathway,M010,1,0
1,0,0,-2.3,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
0,1,0,0,-2.5,0,GO:2001243,negative regulation of intrinsic apoptotic signaling pathway,M010,1,0
1,0,0,-2.2,0,0,hsa05020,Prion disease,M100,1,0
1,0,0,-4,0,0,GO:0002064,epithelial cell development,M100,1,0
0,0,1,0,0,-2.8,GO:0050678,regulation of epithelial cell proliferation,M001,1,0
1,0,0,-2.3,0,0,GO:0010469,regulation of signaling receptor activity,M100,1,0
1,0,0,-2.4,0,0,GO:0002287,alpha-beta T cell activation involved in immune response,M100,1,0
1,0,0,-3.3,0,0,GO:0045652,regulation of megakaryocyte differentiation,M100,1,0
0,1,0,0,-2.9,0,GO:0030833,regulation of actin filament polymerization,M010,1,0
1,0,0,-2.5,0,0,GO:0035148,tube formation,M100,1,0
1,0,0,-3.6,0,0,WP2261,Glioblastoma signaling pathways,M100,1,0
1,0,0,-2.2,0,0,GO:0033173,calcineurin-NFAT signaling cascade,M100,1,0
1,0,0,-2.3,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
0,1,0,0,-3.8,0,GO:0032695,negative regulation of interleukin-12 production,M010,1,0
1,0,0,-2.4,0,0,WP5220,Metabolic reprogramming in pancreatic cancer,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M100,1,0
1,0,0,-3.4,0,0,GO:0006968,cellular defense response,M100,1,0
1,0,0,-4.1,0,0,GO:0050769,positive regulation of neurogenesis,M100,1,0
0,1,0,0,-2.4,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-3,0,0,GO:0048871,multicellular organismal-level homeostasis,M100,1,0
1,0,0,-2.6,0,0,GO:1990868,response to chemokine,M100,1,0
0,1,0,0,-2.1,0,GO:0030500,regulation of bone mineralization,M010,1,0
0,0,1,0,0,-2.3,GO:0051129,negative regulation of cellular component organization,M001,1,0
1,0,0,-3.9,0,0,GO:0001568,blood vessel development,M100,1,0
0,1,0,0,-3.2,0,GO:0043300,regulation of leukocyte degranulation,M010,1,0
0,1,0,0,-5,0,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M010,1,0
1,0,0,-2.2,0,0,GO:0045670,regulation of osteoclast differentiation,M100,1,0
1,0,0,-2.7,0,0,GO:0002645,positive regulation of tolerance induction,M100,1,0
1,0,0,-3.6,0,0,GO:0048469,cell maturation,M100,1,0
0,1,0,0,-2.2,0,GO:0090314,positive regulation of protein targeting to membrane,M010,1,0
0,1,0,0,-2.3,0,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M010,1,0
0,0,1,0,0,-3,R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,M001,1,0
1,0,0,-3.2,0,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M100,1,0
0,1,0,0,-4.2,0,hsa04015,Rap1 signaling pathway,M010,1,0
1,0,0,-2.6,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
0,1,0,0,-3.8,0,GO:0034616,response to laminar fluid shear stress,M010,1,0
1,0,0,-5.1,0,0,GO:0002758,innate immune response-activating signaling pathway,M100,1,0
1,0,0,-3,0,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M100,1,0
1,0,0,-2.6,0,0,WP304,Kit receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M100,1,0
1,0,0,-3,0,0,GO:0016032,viral process,M100,1,0
0,1,0,0,-2.2,0,WP2878,PPAR alpha pathway,M010,1,0
0,1,0,0,-2.3,0,WP2795,Cardiac hypertrophic response,M010,1,0
1,0,0,-2,0,0,GO:0140894,endolysosomal toll-like receptor signaling pathway,M100,1,0
0,1,0,0,-3.5,0,GO:0071248,cellular response to metal ion,M010,1,0
1,0,0,-2.4,0,0,GO:2000177,regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.6,0,0,GO:0002666,positive regulation of T cell tolerance induction,M100,1,0
0,1,0,0,-2.1,0,hsa04137,Mitophagy - animal,M010,1,0
1,0,0,-3.3,0,0,M270,PID MAPK TRK PATHWAY,M100,1,0
0,1,0,0,-2.8,0,M63,PID AVB3 OPN PATHWAY,M010,1,0
1,0,0,-2.6,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
0,1,0,0,-3.7,0,GO:0032868,response to insulin,M010,1,0
1,0,0,-2,0,0,GO:0035307,positive regulation of protein dephosphorylation,M100,1,0
1,0,0,-2.9,0,0,GO:0002224,toll-like receptor signaling pathway,M100,1,0
1,0,0,-3.9,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-5.1,0,0,GO:0032729,positive regulation of type II interferon production,M100,1,0
0,1,0,0,-2.2,0,M1718,SIG IL4RECEPTOR IN B LYPHOCYTES,M010,1,0
0,1,0,0,-2.2,0,GO:0014741,negative regulation of muscle hypertrophy,M010,1,0
0,1,0,0,-3.1,0,GO:0046777,protein autophosphorylation,M010,1,0
1,0,0,-3.5,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
1,0,0,-6,0,0,GO:0007423,sensory organ development,M100,1,0
0,1,0,0,-4.5,0,WP2263,Androgen receptor network in prostate cancer,M010,1,0
0,1,0,0,-2.5,0,GO:0045185,maintenance of protein location,M010,1,0
0,1,0,0,-2.9,0,GO:0120033,negative regulation of plasma membrane bounded cell projection assembly,M010,1,0
1,0,0,-2.2,0,0,M151,PID AR TF PATHWAY,M100,1,0
1,0,0,-3.1,0,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M100,1,0
1,0,0,-2.8,0,0,GO:0007610,behavior,M100,1,0
1,0,0,-2.3,0,0,WP2873,Aryl hydrocarbon receptor pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0010559,regulation of glycoprotein biosynthetic process,M100,1,0
1,0,0,-5,0,0,R-HSA-1257604,PIP3 activates AKT signaling,M100,1,0
0,0,1,0,0,-5.1,R-HSA-8939246,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,M001,1,0
1,0,0,-2.2,0,0,GO:0060644,mammary gland epithelial cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0002643,regulation of tolerance induction,M100,1,0
1,0,0,-2.7,0,0,GO:0071773,cellular response to BMP stimulus,M100,1,0
0,1,0,0,-2.3,0,hsa05418,Fluid shear stress and atherosclerosis,M010,1,0
1,0,0,-2.9,0,0,GO:0048639,positive regulation of developmental growth,M100,1,0
1,0,0,-2.2,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
0,1,0,0,-2,0,hsa04973,Carbohydrate digestion and absorption,M010,1,0
1,0,0,-2.3,0,0,GO:1902692,regulation of neuroblast proliferation,M100,1,0
0,1,0,0,-2.3,0,GO:0042327,positive regulation of phosphorylation,M010,1,0
0,1,0,0,-2.2,0,GO:0070849,response to epidermal growth factor,M010,1,0
1,0,0,-3.7,0,0,GO:0030225,macrophage differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0140895,cell surface toll-like receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0002664,regulation of T cell tolerance induction,M100,1,0
0,0,1,0,0,-4.4,R-HSA-8951936,RUNX3 regulates p14-ARF,M001,1,0
0,1,0,0,-2,0,GO:0071425,hematopoietic stem cell proliferation,M010,1,0
1,0,0,-3,0,0,GO:0035050,embryonic heart tube development,M100,1,0
1,0,0,-3.5,0,0,GO:0032760,positive regulation of tumor necrosis factor production,M100,1,0
0,1,0,0,-2.9,0,WP3646,Hepatitis C and hepatocellular carcinoma,M010,1,0
1,0,0,-4.5,0,0,GO:0048729,tissue morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:1905063,regulation of vascular associated smooth muscle cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0061030,epithelial cell differentiation involved in mammary gland alveolus development,M100,1,0
1,0,0,-2.4,0,0,hsa05150,Staphylococcus aureus infection,M100,1,0
0,1,0,0,-2.4,0,GO:1904018,positive regulation of vasculature development,M010,1,0
1,0,0,-3.3,0,0,GO:0048754,branching morphogenesis of an epithelial tube,M100,1,0
0,1,0,0,-3.4,0,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M010,1,0
0,1,0,0,-2.4,0,WP2037,Prolactin signaling pathway,M010,1,0
0,0,1,0,0,-2.2,GO:0090287,regulation of cellular response to growth factor stimulus,M001,1,0
1,0,0,-4.5,0,0,GO:0048638,regulation of developmental growth,M100,1,0
1,0,0,-3.8,0,0,GO:0042472,inner ear morphogenesis,M100,1,0
0,1,0,0,-2.4,0,hsa05340,Primary immunodeficiency,M010,1,0
0,1,0,0,-2.2,0,GO:0032736,positive regulation of interleukin-13 production,M010,1,0
1,0,0,-2.6,0,0,R-HSA-1489509,DAG and IP3 signaling,M100,1,0
0,1,0,0,-2.8,0,GO:0071453,cellular response to oxygen levels,M010,1,0
0,1,0,0,-5.3,0,GO:0071499,cellular response to laminar fluid shear stress,M010,1,0
1,0,0,-2.5,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
1,0,0,-3.1,0,0,R-HSA-8849473,PTK6 Expression,M100,1,0
1,0,0,-4,0,0,GO:0031343,positive regulation of cell killing,M100,1,0
0,1,0,0,-2.5,0,GO:0019370,leukotriene biosynthetic process,M010,1,0
1,0,0,-3.2,0,0,R-HSA-112043,PLC beta mediated events,M100,1,0
1,0,0,-2.1,0,0,GO:0001525,angiogenesis,M100,1,0
0,1,0,0,-2.1,0,GO:0031401,positive regulation of protein modification process,M010,1,0
0,1,0,0,-2,0,GO:0001704,formation of primary germ layer,M010,1,0
1,0,0,-4.5,0,0,M54,PID IL12 2PATHWAY,M100,1,0
1,0,0,-2.9,0,0,GO:0045927,positive regulation of growth,M100,1,0
1,0,0,-2.1,0,0,hsa04144,Endocytosis,M100,1,0
1,0,0,-3.1,0,0,GO:0050672,negative regulation of lymphocyte proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0006366,transcription by RNA polymerase II,M100,1,0
0,1,0,0,-2.5,0,GO:0010883,regulation of lipid storage,M010,1,0
1,0,0,-2.2,0,0,GO:0045059,positive thymic T cell selection,M100,1,0
1,0,0,-3.1,0,0,GO:0030855,epithelial cell differentiation,M100,1,0
0,1,0,0,-3,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M010,1,0
0,1,0,0,-2.7,0,GO:0043313,regulation of neutrophil degranulation,M010,1,0
0,1,0,0,-2.5,0,GO:0007265,Ras protein signal transduction,M010,1,0
1,0,0,-2.2,0,0,GO:0001649,osteoblast differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0002221,pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.7,0,0,WP707,DNA damage response,M100,1,0
0,1,0,0,-2,0,GO:0010038,response to metal ion,M010,1,0
1,0,0,-2.2,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
0,0,1,0,0,-2.1,GO:0060538,skeletal muscle organ development,M001,1,0
1,0,0,-2.2,0,0,GO:0034599,cellular response to oxidative stress,M100,1,0
0,1,0,0,-2.7,0,GO:0001934,positive regulation of protein phosphorylation,M010,1,0
0,1,0,0,-2.2,0,GO:0002827,positive regulation of T-helper 1 type immune response,M010,1,0
0,1,0,0,-2.6,0,hsa05226,Gastric cancer,M010,1,0
1,0,0,-3.8,0,0,hsa05162,Measles,M100,1,0
1,0,0,-2.2,0,0,WP4884,Pathogenesis of SARS CoV 2 mediated by nsp9 nsp10 complex,M100,1,0
1,0,0,-2.8,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:1903351,cellular response to dopamine,M100,1,0
1,0,0,-3.1,0,0,CORUM:6418,C1q complex,M100,1,0
1,0,0,-2.1,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-2.2,0,0,GO:0032350,regulation of hormone metabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0032733,positive regulation of interleukin-10 production,M100,1,0
0,1,0,0,-3.9,0,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M010,1,0
1,0,0,-2.3,0,0,GO:0040014,regulation of multicellular organism growth,M100,1,0
1,0,0,-3,0,0,R-HSA-112040,G-protein mediated events,M100,1,0
1,0,0,-2.2,0,0,GO:0050732,negative regulation of peptidyl-tyrosine phosphorylation,M100,1,0
0,1,0,0,-2,0,GO:0035590,purinergic nucleotide receptor signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0003143,embryonic heart tube morphogenesis,M100,1,0
1,0,0,-2,0,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M100,1,0
0,1,0,0,-2.7,0,GO:0042594,response to starvation,M010,1,0
1,0,0,-3.2,0,0,WP481,Insulin signaling,M100,1,0
0,0,1,0,0,-2.8,R-HSA-446203,Asparagine N-linked glycosylation,M001,1,0
0,1,0,0,-3.3,0,M15,PID LYSOPHOSPHOLIPID PATHWAY,M010,1,0
0,1,0,0,-3.8,0,GO:0071241,cellular response to inorganic substance,M010,1,0
1,0,0,-2.4,0,0,GO:0090103,cochlea morphogenesis,M100,1,0
1,0,0,-4.5,0,0,GO:0042116,macrophage activation,M100,1,0
1,0,0,-2.8,0,0,GO:0061371,determination of heart left/right asymmetry,M100,1,0
1,0,0,-2.5,0,0,GO:0007420,brain development,M100,1,0
1,0,0,-2.2,0,0,R-HSA-8934593,Regulation of RUNX1 Expression and Activity,M100,1,0
1,0,0,-2,0,0,GO:0072175,epithelial tube formation,M100,1,0
0,1,0,0,-2.3,0,GO:0030206,chondroitin sulfate biosynthetic process,M010,1,0
1,0,0,-2.2,0,0,GO:0010001,glial cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0035051,cardiocyte differentiation,M100,1,0
1,0,0,-4.2,0,0,GO:0001654,eye development,M100,1,0
1,0,0,-2.2,0,0,GO:0055123,digestive system development,M100,1,0
1,0,0,-2.5,0,0,WP530,Cytokines and inflammatory response,M100,1,0
1,0,0,-2,0,0,GO:0150076,neuroinflammatory response,M100,1,0
1,0,0,-2.4,0,0,GO:0002711,positive regulation of T cell mediated immunity,M100,1,0
0,1,0,0,-4.1,0,hsa05130,Pathogenic Escherichia coli infection,M010,1,0
0,1,0,0,-2.3,0,WP4141,PI3K AKT mTOR vitamin D3 signaling,M010,1,0
0,0,1,0,0,-2,GO:0043413,macromolecule glycosylation,M001,1,0
1,0,0,-2.4,0,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M100,1,0
0,0,1,0,0,-2.1,GO:0031333,negative regulation of protein-containing complex assembly,M001,1,0
1,0,0,-2.7,0,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M100,1,0
1,0,0,-4.2,0,0,hsa04620,Toll-like receptor signaling pathway,M100,1,0
1,0,0,-6,0,0,M115,PID REG GR PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0070571,negative regulation of neuron projection regeneration,M100,1,0
1,0,0,-2.6,0,0,GO:1990869,cellular response to chemokine,M100,1,0
0,0,1,0,0,-2.1,GO:0051604,protein maturation,M001,1,0
0,1,0,0,-3,0,WP4928,MAPK pathway in congenital thyroid cancer,M010,1,0
0,0,1,0,0,-2.2,GO:0050890,cognition,M001,1,0
1,0,0,-2,0,0,GO:0009648,photoperiodism,M100,1,0
1,0,0,-4.3,0,0,hsa05321,Inflammatory bowel disease,M100,1,0
1,0,0,-2.6,0,0,GO:0019080,viral gene expression,M100,1,0
1,0,0,-2,0,0,GO:0042102,positive regulation of T cell proliferation,M100,1,0
1,0,0,-2.9,0,0,WP364,IL6 signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0050832,defense response to fungus,M100,1,0
0,0,1,0,0,-2.1,GO:0021885,forebrain cell migration,M001,1,0
0,1,0,0,-2.2,0,GO:0000302,response to reactive oxygen species,M010,1,0
0,1,0,0,-2.1,0,hsa05220,Chronic myeloid leukemia,M010,1,0
1,0,0,-2.2,0,0,R-HSA-2990846,SUMOylation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-186763,Downstream signal transduction,M100,1,0
1,0,0,-2.8,0,0,GO:0051147,regulation of muscle cell differentiation,M100,1,0
0,1,0,0,-2.5,0,WP2879,Farnesoid X receptor pathway,M010,1,0
1,0,0,-2.5,0,0,GO:1990840,response to lectin,M100,1,0
0,0,1,0,0,-2.3,GO:0045069,regulation of viral genome replication,M001,1,0
0,1,0,0,-2.5,0,M8,PID ENDOTHELIN PATHWAY,M010,1,0
0,0,1,0,0,-2.7,GO:1903509,liposaccharide metabolic process,M001,1,0
0,1,0,0,-2.7,0,GO:0015732,prostaglandin transport,M010,1,0
1,0,0,-4.2,0,0,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M100,1,0
1,0,0,-3.6,0,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M100,1,0
0,1,0,0,-3.7,0,GO:0018108,peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-2.2,0,0,GO:0090009,primitive streak formation,M100,1,0
0,1,0,0,-2,0,GO:0048259,regulation of receptor-mediated endocytosis,M010,1,0
0,1,0,0,-4.1,0,GO:1904994,regulation of leukocyte adhesion to vascular endothelial cell,M010,1,0
1,0,0,-4.7,0,0,hsa04625,C-type lectin receptor signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0045622,regulation of T-helper cell differentiation,M010,1,0
1,0,0,-5.4,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M100,1,0
0,1,0,0,-3.5,0,M275,PID ALPHA SYNUCLEIN PATHWAY,M010,1,0
0,1,0,0,-2.4,0,R-HSA-448424,Interleukin-17 signaling,M010,1,0
1,0,0,-2.7,0,0,GO:0042088,T-helper 1 type immune response,M100,1,0
1,0,0,-3.4,0,0,GO:0009799,specification of symmetry,M100,1,0
1,0,0,-2.2,0,0,WP4970,Galanin receptor pathway,M100,1,0
1,0,0,-6.2,0,0,GO:0071407,cellular response to organic cyclic compound,M100,1,0
1,0,0,-4.8,0,0,GO:0035162,embryonic hemopoiesis,M100,1,0
0,1,0,0,-2.2,0,GO:0150077,regulation of neuroinflammatory response,M010,1,0
0,1,0,0,-2.1,0,GO:0032970,regulation of actin filament-based process,M010,1,0
1,0,0,-2.2,0,0,GO:0007200,phospholipase C-activating G protein-coupled receptor signaling pathway,M100,1,0
1,0,0,-2.5,0,0,WP1591,Heart development,M100,1,0
0,1,0,0,-2,0,GO:0042092,type 2 immune response,M010,1,0
1,0,0,-2.5,0,0,R-HSA-9818027,NFE2L2 regulating anti-oxidant/detoxification enzymes,M100,1,0
0,0,1,0,0,-2.1,GO:0048525,negative regulation of viral process,M001,1,0
0,1,0,0,-3.2,0,GO:0002825,regulation of T-helper 1 type immune response,M010,1,0
0,1,0,0,-2,0,GO:0032930,positive regulation of superoxide anion generation,M010,1,0
1,0,0,-3.1,0,0,GO:0032653,regulation of interleukin-10 production,M100,1,0
1,0,0,-4.4,0,0,GO:0150063,visual system development,M100,1,0
1,0,0,-2.4,0,0,GO:0021537,telencephalon development,M100,1,0
1,0,0,-2.4,0,0,WP4217,Ebola virus infection in host,M100,1,0
0,1,0,0,-2.1,0,GO:0060070,canonical Wnt signaling pathway,M010,1,0
1,0,0,-3,0,0,R-HSA-6807070,PTEN Regulation,M100,1,0
0,0,1,0,0,-2.5,GO:0010976,positive regulation of neuron projection development,M001,1,0
0,1,0,0,-2.3,0,R-HSA-4641265,Repression of WNT target genes,M010,1,0
0,1,0,0,-2.4,0,GO:0002639,positive regulation of immunoglobulin production,M010,1,0
1,0,0,-3.1,0,0,GO:2000178,negative regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-5.3,0,0,GO:0007389,pattern specification process,M100,1,0
0,1,0,0,-2.2,0,GO:0090322,regulation of superoxide metabolic process,M010,1,0
1,0,0,-3.4,0,0,M113,PID NFAT 3PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M010,1,0
0,1,0,0,-2.1,0,hsa05160,Hepatitis C,M010,1,0
1,0,0,-2,0,0,M219,PID HEDGEHOG GLI PATHWAY,M100,1,0
0,0,1,0,0,-3.7,GO:0021846,cell proliferation in forebrain,M001,1,0
0,1,0,0,-2.3,0,GO:0060135,maternal process involved in female pregnancy,M010,1,0
1,0,0,-2,0,0,CORUM:642,CtBP complex,M100,1,0
1,0,0,-2,0,0,GO:0035113,embryonic appendage morphogenesis,M100,1,0
1,0,0,-2.8,0,0,GO:0045444,fat cell differentiation,M100,1,0
0,1,0,0,-3.2,0,GO:0032787,monocarboxylic acid metabolic process,M010,1,0
0,1,0,0,-2.9,0,GO:0045655,regulation of monocyte differentiation,M010,1,0
0,1,0,0,-2,0,GO:0006690,icosanoid metabolic process,M010,1,0
0,1,0,0,-2.5,0,GO:0043903,regulation of biological process involved in symbiotic interaction,M010,1,0
0,1,0,0,-2,0,GO:0010876,lipid localization,M010,1,0
1,0,0,-2.1,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-4.8,0,0,GO:0032663,regulation of interleukin-2 production,M100,1,0
1,0,0,-2.4,0,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M100,1,0
1,0,0,-3.3,0,0,GO:0014015,positive regulation of gliogenesis,M100,1,0
0,1,0,0,-2.3,0,hsa01523,Antifolate resistance,M010,1,0
1,0,0,-2.2,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
1,0,0,-2.2,0,0,GO:0097011,cellular response to granulocyte macrophage colony-stimulating factor stimulus,M100,1,0
1,0,0,-2.7,0,0,hsa05217,Basal cell carcinoma,M100,1,0
0,1,0,0,-2.5,0,WP408,Oxidative stress response,M010,1,0
0,1,0,0,-2.6,0,GO:0006631,fatty acid metabolic process,M010,1,0
1,0,0,-2.2,0,0,R-HSA-9700645,ALK mutants bind TKIs,M100,1,0
1,0,0,-2.6,0,0,GO:0032763,regulation of mast cell cytokine production,M100,1,0
1,0,0,-2,0,0,GO:0042119,neutrophil activation,M100,1,0
0,1,0,0,-3.3,0,GO:0006914,autophagy,M010,1,0
0,1,0,0,-2.8,0,GO:0043392,negative regulation of DNA binding,M010,1,0
0,1,0,0,-2.4,0,M45,PID CD40 PATHWAY,M010,1,0
1,0,0,-3.3,0,0,GO:0032673,regulation of interleukin-4 production,M100,1,0
0,1,0,0,-2.3,0,hsa00532,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,M010,1,0
0,1,0,0,-2,0,GO:0050650,chondroitin sulfate proteoglycan biosynthetic process,M010,1,0
1,0,0,-2.4,0,0,GO:0032526,response to retinoic acid,M100,1,0
0,1,0,0,-2.3,0,GO:0043923,positive regulation by host of viral transcription,M010,1,0
1,0,0,-6.3,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M100,1,0
0,1,0,0,-3.7,0,GO:0060627,regulation of vesicle-mediated transport,M010,1,0
1,0,0,-2.6,0,0,hsa04934,Cushing syndrome,M100,1,0
0,1,0,0,-5.3,0,hsa04666,Fc gamma R-mediated phagocytosis,M010,1,0
1,0,0,-3.7,0,0,GO:0032479,regulation of type I interferon production,M100,1,0
1,0,0,-3.1,0,0,GO:0060972,left/right pattern formation,M100,1,0
0,1,0,0,-2.5,0,GO:0034405,response to fluid shear stress,M010,1,0
1,0,0,-2.6,0,0,GO:0045589,regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-4,0,0,GO:0040008,regulation of growth,M100,1,0
1,0,0,-3.2,0,0,R-HSA-388841,Costimulation by the CD28 family,M100,1,0
1,0,0,-3.1,0,0,GO:0042471,ear morphogenesis,M100,1,0
1,0,0,-3.1,0,0,R-HSA-2025928,Calcineurin activates NFAT,M100,1,0
1,0,0,-2.2,0,0,WP1545,miRNAs involved in DNA damage response,M100,1,0
1,0,0,-3.8,0,0,WP3599,Transcription factor regulation in adipogenesis,M100,1,0
1,0,0,-3.9,0,0,GO:0048863,stem cell differentiation,M100,1,0
1,0,0,-3,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-2.2,0,0,GO:0046016,positive regulation of transcription by glucose,M100,1,0
0,1,0,0,-4.4,0,GO:0071375,cellular response to peptide hormone stimulus,M010,1,0
1,0,0,-2.1,0,0,GO:0002070,epithelial cell maturation,M100,1,0
1,0,0,-2.2,0,0,WP2814,Mammary gland development pathway Puberty Stage 2 of 4,M100,1,0
0,0,1,0,0,-2.9,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,M001,1,0
1,0,0,-2.3,0,0,R-HSA-2262752,Cellular responses to stress,M100,1,0
0,1,0,0,-2.9,0,GO:0097242,amyloid-beta clearance,M010,1,0
1,0,0,-2.7,0,0,R-HSA-9700206,Signaling by ALK in cancer,M100,1,0
0,1,0,0,-2.3,0,GO:0018904,ether metabolic process,M010,1,0
0,1,0,0,-2.1,0,R-HSA-5632684,Hedgehog 'on' state,M010,1,0
1,0,0,-3.5,0,0,GO:0060216,definitive hemopoiesis,M100,1,0
0,1,0,0,-2.2,0,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M010,1,0
1,0,0,-3.3,0,0,GO:0048534,hematopoietic or lymphoid organ development,M100,1,0
1,0,0,-2,0,0,GO:0030326,embryonic limb morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0002752,cell surface pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0035306,positive regulation of dephosphorylation,M100,1,0
1,0,0,-2.8,0,0,WP2023,Cell differentiation expanded index,M100,1,0
0,1,0,0,-2.2,0,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M010,1,0
1,0,0,-2.2,0,0,WP170,Nuclear receptors,M100,1,0
1,0,0,-2.7,0,0,WP3893,Development and heterogeneity of the ILC family,M100,1,0
1,0,0,-3.5,0,0,GO:0007507,heart development,M100,1,0
0,1,0,0,-2.5,0,GO:0045765,regulation of angiogenesis,M010,1,0
1,0,0,-4,0,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-3.1,0,0,GO:0032945,negative regulation of mononuclear cell proliferation,M100,1,0
0,1,0,0,-2.4,0,GO:0051651,maintenance of location in cell,M010,1,0
1,0,0,-4.7,0,0,GO:0030101,natural killer cell activation,M100,1,0
1,0,0,-2.2,0,0,WP5102,Familial partial lipodystrophy,M100,1,0
1,0,0,-2.2,0,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2.2,0,0,R-HSA-9827857,Specification of primordial germ cells,M100,1,0
1,0,0,-2.3,0,0,GO:0001709,cell fate determination,M100,1,0
0,0,1,0,0,-2.2,GO:0007519,skeletal muscle tissue development,M001,1,0
0,1,0,0,-2.2,0,GO:0030204,chondroitin sulfate metabolic process,M010,1,0
1,0,0,-3.1,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M100,1,0
0,1,0,0,-2.3,0,R-HSA-201556,Signaling by ALK,M010,1,0
0,1,0,0,-2.4,0,GO:2001234,negative regulation of apoptotic signaling pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0070059,intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress,M100,1,0
1,0,0,-4.5,0,0,GO:0008285,negative regulation of cell population proliferation,M100,1,0
1,0,0,-3.1,0,0,GO:0021772,olfactory bulb development,M100,1,0
0,0,1,0,0,-2.6,R-HSA-1912422,Pre-NOTCH Expression and Processing,M001,1,0
0,1,0,0,-3.2,0,GO:1902532,negative regulation of intracellular signal transduction,M010,1,0
1,0,0,-4.8,0,0,GO:0098657,import into cell,M100,1,0
1,0,0,-2.8,0,0,GO:0003151,outflow tract morphogenesis,M100,1,0
0,1,0,0,-2.7,0,R-HSA-354192,Integrin signaling,M010,1,0
1,0,0,-5.5,0,0,GO:0032496,response to lipopolysaccharide,M100,1,0
1,0,0,-2.8,0,0,GO:0007498,mesoderm development,M100,1,0
1,0,0,-2.3,0,0,GO:0050852,T cell receptor signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0017157,regulation of exocytosis,M010,1,0
0,1,0,0,-2.6,0,GO:1902106,negative regulation of leukocyte differentiation,M010,1,0
0,1,0,0,-2.2,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M010,1,0
0,1,0,0,-2.6,0,GO:0032956,regulation of actin cytoskeleton organization,M010,1,0
1,0,0,-2,0,0,GO:0048821,erythrocyte development,M100,1,0
0,1,0,0,-2.1,0,GO:0010611,regulation of cardiac muscle hypertrophy,M010,1,0
0,0,1,0,0,-2.9,R-HSA-74158,RNA Polymerase III Transcription,M001,1,0
1,0,0,-4.3,0,0,GO:0002009,morphogenesis of an epithelium,M100,1,0
0,0,1,0,0,-3.1,GO:0090162,establishment of epithelial cell polarity,M001,1,0
0,1,0,0,-2.9,0,WP5385,Growth factors and hormones in Beta cell proliferation,M010,1,0
0,1,0,0,-2.1,0,GO:0032271,regulation of protein polymerization,M010,1,0
1,0,0,-2,0,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M100,1,0
0,1,0,0,-2.2,0,M110,PID IL1 PATHWAY,M010,1,0
1,0,0,-3.2,0,0,GO:0070482,response to oxygen levels,M100,1,0
0,1,0,0,-2.8,0,GO:2000191,regulation of fatty acid transport,M010,1,0
1,0,0,-2.1,0,0,GO:0042060,wound healing,M100,1,0
1,0,0,-3.1,0,0,WP4146,Macrophage markers,M100,1,0
1,0,0,-2.2,0,0,GO:0046015,regulation of transcription by glucose,M100,1,0
1,0,0,-2,0,0,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M100,1,0
0,1,0,0,-2.2,0,GO:0002443,leukocyte mediated immunity,M010,1,0
1,0,0,-2.8,0,0,GO:0060021,roof of mouth development,M100,1,0
1,0,0,-2.4,0,0,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M100,1,0
0,1,0,0,-2.2,0,GO:0034103,regulation of tissue remodeling,M010,1,0
0,0,1,0,0,-2.5,R-HSA-948021,Transport to the Golgi and subsequent modification,M001,1,0
0,1,0,0,-2.2,0,hsa04072,Phospholipase D signaling pathway,M010,1,0
1,0,0,-2.2,0,0,WP2032,Thyroid stimulating hormone TSH signaling pathway,M100,1,0
0,1,0,0,-2.8,0,R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),M010,1,0
0,1,0,0,-2.8,0,WP4155,Endometrial cancer,M010,1,0
0,0,1,0,0,-2.1,GO:0009101,glycoprotein biosynthetic process,M001,1,0
1,0,0,-2.2,0,0,GO:0001666,response to hypoxia,M100,1,0
0,1,0,0,-3.3,0,GO:1904996,positive regulation of leukocyte adhesion to vascular endothelial cell,M010,1,0
1,0,0,-5,0,0,GO:0006897,endocytosis,M100,1,0
0,1,0,0,-2.6,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M010,1,0
1,0,0,-5.3,0,0,GO:0050767,regulation of neurogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0021988,olfactory lobe development,M100,1,0
1,0,0,-2.2,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
1,0,0,-2,0,0,GO:0090102,cochlea development,M100,1,0
1,0,0,-2.4,0,0,GO:0042475,odontogenesis of dentin-containing tooth,M100,1,0
1,0,0,-6.6,0,0,GO:0009792,embryo development ending in birth or egg hatching,M100,1,0
0,1,0,0,-2.4,0,GO:1902905,positive regulation of supramolecular fiber organization,M010,1,0
1,0,0,-3.2,0,0,GO:0042742,defense response to bacterium,M100,1,0
1,0,0,-2,0,0,GO:1900274,regulation of phospholipase C activity,M100,1,0
1,0,0,-5.2,0,0,GO:0048562,embryonic organ morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0038093,Fc receptor signaling pathway,M100,1,0
0,1,0,0,-2.4,0,hsa04921,Oxytocin signaling pathway,M010,1,0
0,1,0,0,-3.4,0,hsa04932,Non-alcoholic fatty liver disease,M010,1,0
1,0,0,-2.9,0,0,WP3858,Toll like receptor signaling related to MyD88,M100,1,0
1,0,0,-2.6,0,0,GO:0019083,viral transcription,M100,1,0
1,0,0,-2.8,0,0,GO:0048546,digestive tract morphogenesis,M100,1,0
1,0,0,-2.8,0,0,M118,PID INTEGRIN A9B1 PATHWAY,M100,1,0
1,0,0,-3.6,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
1,0,0,-2.2,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
0,1,0,0,-3.3,0,GO:0071498,cellular response to fluid shear stress,M010,1,0
0,1,0,0,-3.1,0,GO:0034612,response to tumor necrosis factor,M010,1,0
0,1,0,0,-2.3,0,GO:0010614,negative regulation of cardiac muscle hypertrophy,M010,1,0
0,1,0,0,-2.2,0,hsa05140,Leishmaniasis,M010,1,0
0,1,0,0,-2.8,0,GO:0042832,defense response to protozoan,M010,1,0
1,0,0,-3,0,0,GO:0048839,inner ear development,M100,1,0
0,0,1,0,0,-2.9,WP474,Endochondral ossification,M001,1,0
1,0,0,-2.6,0,0,GO:1904149,regulation of microglial cell mediated cytotoxicity,M100,1,0
1,0,0,-3.4,0,0,WP2328,Allograft rejection,M100,1,0
0,1,0,0,-2.3,0,GO:0002830,positive regulation of type 2 immune response,M010,1,0
1,0,0,-6.8,0,0,GO:0043009,chordate embryonic development,M100,1,0
0,1,0,0,-2.2,0,GO:0006869,lipid transport,M010,1,0
0,0,1,0,0,-2.9,WP4808,Endochondral ossification with skeletal dysplasias,M001,1,0
1,0,0,-9.1,0,0,GO:0048568,embryonic organ development,M100,1,0
1,0,0,-3.1,0,0,GO:0090398,cellular senescence,M100,1,0
0,1,0,0,-3.1,0,GO:0010324,membrane invagination,M010,1,0
0,1,0,0,-4.3,0,GO:0002861,regulation of inflammatory response to antigenic stimulus,M010,1,0
0,1,0,0,-3.8,0,M193,PID NEPHRIN NEPH1 PATHWAY,M010,1,0
0,0,1,0,0,-2.2,GO:0008630,intrinsic apoptotic signaling pathway in response to DNA damage,M001,1,0
1,0,0,-2.7,0,0,GO:0071772,response to BMP,M100,1,0
1,0,0,-3.3,0,0,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M100,1,0
0,1,0,0,-2.5,0,WP4396,Nonalcoholic fatty liver disease,M010,1,0
0,1,0,0,-2.6,0,GO:1904950,negative regulation of establishment of protein localization,M010,1,0
1,0,0,-3.7,0,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M100,1,0
1,0,0,-4.4,0,0,WP4630,Measles virus infection,M100,1,0
0,0,1,0,0,-2.6,GO:0045071,negative regulation of viral genome replication,M001,1,0
1,0,0,-7,0,0,GO:0035239,tube morphogenesis,M100,1,0
1,0,0,-2.3,0,0,hsa05230,Central carbon metabolism in cancer,M100,1,0
1,0,0,-4.3,0,0,WP75,Toll like receptor signaling pathway,M100,1,0
1,0,0,-4,0,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-3.5,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.8,0,0,GO:0002706,regulation of lymphocyte mediated immunity,M100,1,0
0,1,0,0,-3.6,0,GO:0071715,icosanoid transport,M010,1,0
0,1,0,0,-2.8,0,hsa04920,Adipocytokine signaling pathway,M010,1,0
0,1,0,0,-3.7,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M010,1,0
1,0,0,-2.9,0,0,GO:0001947,heart looping,M100,1,0
1,0,0,-2.5,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0032507,maintenance of protein location in cell,M010,1,0
0,1,0,0,-2.1,0,GO:0030162,regulation of proteolysis,M010,1,0
1,0,0,-2.8,0,0,GO:0048844,artery morphogenesis,M100,1,0
1,0,0,-4.8,0,0,GO:0060562,epithelial tube morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0042130,negative regulation of T cell proliferation,M100,1,0
0,1,0,0,-2.1,0,GO:0042176,regulation of protein catabolic process,M010,1,0
0,1,0,0,-3,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M010,1,0
0,1,0,0,-2.2,0,GO:0050729,positive regulation of inflammatory response,M010,1,0
0,1,0,0,-2.4,0,GO:0030832,regulation of actin filament length,M010,1,0
1,0,0,-2.2,0,0,WP3926,ApoE and miR 146 in inflammation and atherosclerosis,M100,1,0
0,1,0,0,-2.8,0,GO:0043302,positive regulation of leukocyte degranulation,M010,1,0
1,0,0,-2,0,0,GO:0090183,regulation of kidney development,M100,1,0
0,1,0,0,-3.8,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M010,1,0
0,1,0,0,-2.3,0,GO:0001893,maternal placenta development,M010,1,0
1,0,0,-2.2,0,0,GO:0046633,alpha-beta T cell proliferation,M100,1,0
0,1,0,0,-2.6,0,GO:0001562,response to protozoan,M010,1,0
0,1,0,0,-2.7,0,GO:0030854,positive regulation of granulocyte differentiation,M010,1,0
1,0,0,-3.6,0,0,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
0,1,0,0,-2.1,0,GO:0045766,positive regulation of angiogenesis,M010,1,0
1,0,0,-3.4,0,0,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
1,0,0,-6,0,0,GO:0048598,embryonic morphogenesis,M100,1,0
0,1,0,0,-2.3,0,M211,PID HEDGEHOG 2PATHWAY,M010,1,0
1,0,0,-2.2,0,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M100,1,0
1,0,0,-2.7,0,0,GO:0050900,leukocyte migration,M100,1,0
1,0,0,-2.3,0,0,GO:0002724,regulation of T cell cytokine production,M100,1,0
0,1,0,0,-2.6,0,M169,PID INTEGRIN2 PATHWAY,M010,1,0
0,1,0,0,-2.5,0,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M010,1,0
0,1,0,0,-4.3,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-2.5,0,0,GO:0061180,mammary gland epithelium development,M100,1,0
1,0,0,-2.5,0,0,GO:0060074,synapse maturation,M100,1,0
1,0,0,-4.8,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
1,0,0,-2.2,0,0,WP299,Nuclear receptors in lipid metabolism and toxicity,M100,1,0
0,0,1,0,0,-2.4,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M001,1,0
0,1,0,0,-2.9,0,GO:1905897,regulation of response to endoplasmic reticulum stress,M010,1,0
1,0,0,-2.4,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M100,1,0
0,1,0,0,-3.6,0,GO:0032722,positive regulation of chemokine production,M010,1,0
1,0,0,-2.3,0,0,GO:0071300,cellular response to retinoic acid,M100,1,0
0,0,1,0,0,-4.2,R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,M001,1,0
0,1,0,0,-4,0,WP395,IL 4 signaling pathway,M010,1,0
0,1,0,0,-2.3,0,M257,PID EPHRINB REV PATHWAY,M010,1,0
0,1,0,0,-2,0,M16,PID INSULIN PATHWAY,M010,1,0
1,0,0,-2.6,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0045732,positive regulation of protein catabolic process,M010,1,0
1,0,0,-2.9,0,0,WP4685,Melanoma,M100,1,0
0,1,0,0,-2.5,0,M71,PID ILK PATHWAY,M010,1,0
0,1,0,0,-2.2,0,GO:0051646,mitochondrion localization,M010,1,0
1,0,0,-4,0,0,hsa04915,Estrogen signaling pathway,M100,1,0
0,1,0,0,-2.1,0,M141,PID PI3KCI PATHWAY,M010,1,0
0,1,0,0,-2.1,0,GO:2000060,positive regulation of ubiquitin-dependent protein catabolic process,M010,1,0
0,1,0,0,-3.1,0,GO:1903707,negative regulation of hemopoiesis,M010,1,0
1,0,0,-2.1,0,0,WP2858,Ectoderm differentiation,M100,1,0
1,0,0,-2.9,0,0,GO:0048545,response to steroid hormone,M100,1,0
1,0,0,-2.5,0,0,R-HSA-1433557,Signaling by SCF-KIT,M100,1,0
0,1,0,0,-3.1,0,M143,PID IL2 PI3K PATHWAY,M010,1,0
1,0,0,-2.9,0,0,GO:0002720,positive regulation of cytokine production involved in immune response,M100,1,0
0,1,0,0,-2.3,0,GO:2001233,regulation of apoptotic signaling pathway,M010,1,0
1,0,0,-2.6,0,0,GO:0009629,response to gravity,M100,1,0
0,1,0,0,-2.2,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M010,1,0
1,0,0,-2.1,0,0,GO:0001656,metanephros development,M100,1,0
1,0,0,-5.3,0,0,GO:0048732,gland development,M100,1,0
1,0,0,-5.6,0,0,GO:0032680,regulation of tumor necrosis factor production,M100,1,0
0,1,0,0,-3.4,0,GO:0060491,regulation of cell projection assembly,M010,1,0
0,1,0,0,-4,0,R-HSA-8980692,RHOA GTPase cycle,M010,1,0
1,0,0,-2.8,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-3.6,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
1,0,0,-2.9,0,0,GO:0030900,forebrain development,M100,1,0
0,1,0,0,-2.7,0,WP4950,16p11 2 distal deletion syndrome,M010,1,0
1,0,0,-2.5,0,0,M268,PID S1P S1P2 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0046677,response to antibiotic,M100,1,0
1,0,0,-2,0,0,GO:0009649,entrainment of circadian clock,M100,1,0
0,1,0,0,-2.4,0,GO:0071364,cellular response to epidermal growth factor stimulus,M010,1,0
1,0,0,-2.8,0,0,GO:0050766,positive regulation of phagocytosis,M100,1,0
0,1,0,0,-2.5,0,hsa05213,Endometrial cancer,M010,1,0
1,0,0,-2.6,0,0,R-HSA-9707587,Regulation of HMOX1 expression and activity,M100,1,0
1,0,0,-2.4,0,0,GO:0070633,transepithelial transport,M100,1,0
1,0,0,-2,0,0,hsa04728,Dopaminergic synapse,M100,1,0
0,1,0,0,-3,0,GO:0002576,platelet degranulation,M010,1,0
0,1,0,0,-3.3,0,GO:0032642,regulation of chemokine production,M010,1,0
1,0,0,-2.7,0,0,GO:0032481,positive regulation of type I interferon production,M100,1,0
1,0,0,-3.1,0,0,R-HSA-2562578,TRIF-mediated programmed cell death,M100,1,0
1,0,0,-3.1,0,0,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M100,1,0
0,1,0,0,-3.4,0,GO:1903573,negative regulation of response to endoplasmic reticulum stress,M010,1,0
0,1,0,0,-2.9,0,GO:0030852,regulation of granulocyte differentiation,M010,1,0
1,0,0,-3.3,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
1,0,0,-3.6,0,0,GO:0010464,regulation of mesenchymal cell proliferation,M100,1,0
0,1,0,0,-2.6,0,GO:0032869,cellular response to insulin stimulus,M010,1,0
0,1,0,0,-2.1,0,WP400,p38 MAPK signaling pathway,M010,1,0
0,1,0,0,-2,0,GO:0014743,regulation of muscle hypertrophy,M010,1,0
1,0,0,-2.6,0,0,WP3672,lncRNA mediated mechanisms of therapeutic resistance,M100,1,0
1,0,0,-2.2,0,0,WP5033,Genes associated with the development of rheumatoid arthritis,M100,1,0
1,0,0,-2.2,0,0,GO:0048708,astrocyte differentiation,M100,1,0
0,1,0,0,-3,0,GO:1905952,regulation of lipid localization,M010,1,0
1,0,0,-2.5,0,0,GO:0150146,cell junction disassembly,M100,1,0
0,1,0,0,-3.1,0,M33,PID GLYPICAN 1PATHWAY,M010,1,0
1,0,0,-2.6,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
0,1,0,0,-2.2,0,GO:0045579,positive regulation of B cell differentiation,M010,1,0
1,0,0,-4.2,0,0,GO:0061138,morphogenesis of a branching epithelium,M100,1,0
1,0,0,-3.2,0,0,WP231,TNF alpha signaling pathway,M100,1,0
0,1,0,0,-4,0,R-HSA-9664407,Parasite infection,M010,1,0
1,0,0,-2.6,0,0,R-HSA-173623,Classical antibody-mediated complement activation,M100,1,0
0,1,0,0,-3,0,GO:0006991,response to sterol depletion,M010,1,0
0,1,0,0,-2.5,0,GO:0008064,regulation of actin polymerization or depolymerization,M010,1,0
1,0,0,-2.8,0,0,GO:0009620,response to fungus,M100,1,0
1,0,0,-2.4,0,0,M276,PID FGF PATHWAY,M100,1,0
0,1,0,0,-3,0,WP4919,Neuroinflammation,M010,1,0
0,1,0,0,-2.8,0,GO:1903533,regulation of protein targeting,M010,1,0
0,1,0,0,-3.1,0,hsa04611,Platelet activation,M010,1,0
1,0,0,-5.3,0,0,GO:0071222,cellular response to lipopolysaccharide,M100,1,0
1,0,0,-3.4,0,0,R-HSA-111885,Opioid Signalling,M100,1,0
0,1,0,0,-2,0,M175,PID ERBB2 ERBB3 PATHWAY,M010,1,0
1,0,0,-3.4,0,0,hsa04668,TNF signaling pathway,M100,1,0
1,0,0,-5.3,0,0,GO:0051960,regulation of nervous system development,M100,1,0
0,1,0,0,-3.7,0,GO:0018212,peptidyl-tyrosine modification,M010,1,0
1,0,0,-2.1,0,0,WP5272,LDL influence on CD14 and TLR4,M100,1,0
1,0,0,-5.8,0,0,hsa04148,Efferocytosis,M100,1,0
1,0,0,-4.2,0,0,GO:0021700,developmental maturation,M100,1,0
1,0,0,-2,0,0,R-HSA-389356,CD28 co-stimulation,M100,1,0
0,1,0,0,-2.3,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M010,1,0
1,0,0,-3.1,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M100,1,0
0,1,0,0,-2.3,0,GO:0097028,dendritic cell differentiation,M010,1,0
0,1,0,0,-2.3,0,GO:0031342,negative regulation of cell killing,M010,1,0
1,0,0,-3.1,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
1,0,0,-2.5,0,0,WP3877,MYD88 distinct input output pathway,M100,1,0
1,0,0,-2.6,0,0,M231,PID KIT PATHWAY,M100,1,0
1,0,0,-2.6,0,0,M138,PID THROMBIN PAR4 PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0035270,endocrine system development,M100,1,0
0,1,0,0,-2.2,0,GO:0098926,postsynaptic signal transduction,M010,1,0
1,0,0,-3.8,0,0,R-HSA-202433,Generation of second messenger molecules,M100,1,0
1,0,0,-2.8,0,0,GO:0002281,macrophage activation involved in immune response,M100,1,0
1,0,0,-2.1,0,0,WP5083,Neuroinflammation and glutamatergic signaling,M100,1,0
1,0,0,-5.4,0,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
1,0,0,-2.9,0,0,WP4540,Hippo signaling regulation pathways,M100,1,0
0,1,0,0,-3.3,0,GO:0015908,fatty acid transport,M010,1,0
0,1,0,0,-2.8,0,R-HSA-525793,Myogenesis,M010,1,0
0,1,0,0,-2.1,0,hsa04060,Cytokine-cytokine receptor interaction,M010,1,0
1,0,0,-4.3,0,0,GO:0001763,morphogenesis of a branching structure,M100,1,0
1,0,0,-2.1,0,0,R-HSA-446652,Interleukin-1 family signaling,M100,1,0
0,1,0,0,-2.5,0,R-HSA-9818749,Regulation of NFE2L2 gene expression,M010,1,0
0,1,0,0,-2.1,0,M70,PID PS1 PATHWAY,M010,1,0
0,1,0,0,-3.1,0,GO:0051056,regulation of small GTPase mediated signal transduction,M010,1,0
0,1,0,0,-2.6,0,GO:0110053,regulation of actin filament organization,M010,1,0
1,0,0,-2.7,0,0,GO:0098883,synapse pruning,M100,1,0
1,0,0,-4.8,0,0,GO:0030879,mammary gland development,M100,1,0
1,0,0,-2.4,0,0,hsa04722,Neurotrophin signaling pathway,M100,1,0
0,1,0,0,-2.7,0,M48,PID MET PATHWAY,M010,1,0
0,1,0,0,-2.1,0,GO:0051224,negative regulation of protein transport,M010,1,0
0,1,0,0,-2.1,0,hsa04613,Neutrophil extracellular trap formation,M010,1,0
0,1,0,0,-4.9,0,R-HSA-9674555,Signaling by CSF3 (G-CSF),M010,1,0
0,1,0,0,-3.3,0,hsa04926,Relaxin signaling pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0071383,cellular response to steroid hormone stimulus,M100,1,0
1,0,0,-3.4,0,0,GO:0031663,lipopolysaccharide-mediated signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0097012,response to granulocyte macrophage colony-stimulating factor,M100,1,0
1,0,0,-2.6,0,0,GO:0043380,regulation of memory T cell differentiation,M100,1,0
1,0,0,-3.1,0,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9707616,Heme signaling,M100,1,0
0,1,0,0,-2.5,0,GO:0045581,negative regulation of T cell differentiation,M010,1,0
0,1,0,0,-3.7,0,R-HSA-9013149,RAC1 GTPase cycle,M010,1,0
1,0,0,-3.7,0,0,R-HSA-166166,MyD88-independent TLR4 cascade,M100,1,0
1,0,0,-3.1,0,0,GO:0071346,cellular response to type II interferon,M100,1,0
1,0,0,-4.3,0,0,GO:0048880,sensory system development,M100,1,0
0,1,0,0,-3.2,0,WP5322,CKAP4 signaling pathway map,M010,1,0
1,0,0,-2.2,0,0,R-HSA-198693,AKT phosphorylates targets in the nucleus,M100,1,0
0,1,0,0,-2.4,0,GO:0120031,plasma membrane bounded cell projection assembly,M010,1,0
1,0,0,-3.1,0,0,GO:0070664,negative regulation of leukocyte proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0061043,regulation of vascular wound healing,M100,1,0
0,1,0,0,-2.2,0,R-HSA-2871837,FCERI mediated NF-kB activation,M010,1,0
1,0,0,-2.7,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0045921,positive regulation of exocytosis,M010,1,0
1,0,0,-2.2,0,0,GO:0022612,gland morphogenesis,M100,1,0
0,0,1,0,0,-3.3,GO:0140546,defense response to symbiont,M001,1,0
1,0,0,-5.5,0,0,GO:0032649,regulation of type II interferon production,M100,1,0
1,0,0,-2,0,0,R-HSA-913531,Interferon Signaling,M100,1,0
0,1,0,0,-3.3,0,GO:1902235,regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,M010,1,0
0,1,0,0,-4,0,R-HSA-9664417,Leishmania phagocytosis,M010,1,0
0,1,0,0,-3.3,0,GO:0030031,cell projection assembly,M010,1,0
0,1,0,0,-2,0,WP516,Hypertrophy model,M010,1,0
1,0,0,-3.2,0,0,GO:0007368,determination of left/right symmetry,M100,1,0
0,1,0,0,-2.4,0,GO:0071466,cellular response to xenobiotic stimulus,M010,1,0
0,1,0,0,-2.1,0,GO:0002090,regulation of receptor internalization,M010,1,0
0,1,0,0,-3.4,0,GO:1901503,ether biosynthetic process,M010,1,0
0,1,0,0,-2.4,0,GO:0070201,regulation of establishment of protein localization,M010,1,0
1,0,0,-3.3,0,0,WP5198,Inflammatory bowel disease signaling,M100,1,0
0,1,0,0,-3.7,0,GO:0043030,regulation of macrophage activation,M010,1,0
1,0,0,-2,0,0,GO:0045471,response to ethanol,M100,1,0
0,1,0,0,-2.1,0,GO:1903053,regulation of extracellular matrix organization,M010,1,0
0,1,0,0,-2.4,0,GO:0034614,cellular response to reactive oxygen species,M010,1,0
0,0,1,0,0,-2.5,GO:0031641,regulation of myelination,M001,1,0
1,0,0,-2.9,0,0,GO:0060485,mesenchyme development,M100,1,0
0,1,0,0,-2.4,0,GO:1903307,positive regulation of regulated secretory pathway,M010,1,0
0,1,0,0,-2.1,0,R-HSA-5358351,Signaling by Hedgehog,M010,1,0
1,0,0,-2.4,0,0,GO:0045664,regulation of neuron differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0048681,negative regulation of axon regeneration,M100,1,0
1,0,0,-3,0,0,R-HSA-202430,Translocation of ZAP-70 to Immunological synapse,M100,1,0
1,0,0,-2.3,0,0,WP3941,Oxidative damage response,M100,1,0
0,1,0,0,-2.8,0,GO:0010885,regulation of cholesterol storage,M010,1,0
0,1,0,0,-2.5,0,GO:0009896,positive regulation of catabolic process,M010,1,0
0,1,0,0,-2.1,0,WP5380,5q35 copy number variation,M010,1,0
1,0,0,-2.9,0,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M100,1,0
0,0,1,0,0,-2,GO:0006486,protein glycosylation,M001,1,0
1,0,0,-2.7,0,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M100,1,0
1,0,0,-2.5,0,0,GO:0042100,B cell proliferation,M100,1,0
0,1,0,0,-3,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M010,1,0
1,0,0,-4.5,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
0,1,0,0,-3,0,GO:0032715,negative regulation of interleukin-6 production,M010,1,0
0,1,0,0,-2.2,0,GO:0002430,complement receptor mediated signaling pathway,M010,1,0
0,0,1,0,0,-2.2,GO:0031346,positive regulation of cell projection organization,M001,1,0
1,0,0,-3.7,0,0,GO:0051962,positive regulation of nervous system development,M100,1,0
1,0,0,-2.3,0,0,GO:0060541,respiratory system development,M100,1,0
0,1,0,0,-2.8,0,GO:1901342,regulation of vasculature development,M010,1,0
1,0,0,-3.6,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
1,0,0,-3.5,0,0,GO:0051150,regulation of smooth muscle cell differentiation,M100,1,0
0,1,0,0,-2.8,0,GO:0051051,negative regulation of transport,M010,1,0
0,1,0,0,-2.6,0,GO:0002888,positive regulation of myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-4.7,0,0,GO:0002520,immune system development,M100,1,0
1,0,0,-3.9,0,0,GO:0043010,camera-type eye development,M100,1,0
1,0,0,-2.4,0,0,GO:0090596,sensory organ morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0002709,regulation of T cell mediated immunity,M100,1,0
1,0,0,-2.2,0,0,GO:0048589,developmental growth,M100,1,0
1,0,0,-2.4,0,0,GO:2000648,positive regulation of stem cell proliferation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9818035,NFE2L2 regulating ER-stress associated genes,M100,1,0
1,0,0,-2.9,0,0,GO:0140888,interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP4329,miRNA role in immune response in sepsis,M100,1,0
1,0,0,-2.2,0,0,GO:0050860,negative regulation of T cell receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2.8,0,0,GO:0007162,negative regulation of cell adhesion,M100,1,0
1,0,0,-3.1,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
0,1,0,0,-2.7,0,GO:0050854,regulation of antigen receptor-mediated signaling pathway,M010,1,0
1,0,0,-2.3,0,0,R-HSA-9824446,Viral Infection Pathways,M100,1,0
1,0,0,-2.8,0,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0043408,regulation of MAPK cascade,M100,1,0
0,1,0,0,-2.4,0,GO:0043032,positive regulation of macrophage activation,M010,1,0
1,0,0,-2.7,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9022707,MECP2 regulates transcription factors,M100,1,0
0,1,0,0,-3.1,0,GO:0034113,heterotypic cell-cell adhesion,M010,1,0
1,0,0,-3.6,0,0,WP585,Interferon type I signaling pathways,M100,1,0
1,0,0,-3.6,0,0,GO:0002467,germinal center formation,M100,1,0
1,0,0,-2.2,0,0,GO:1903350,response to dopamine,M100,1,0
1,0,0,-2.2,0,0,M182,PID IL3 PATHWAY,M100,1,0
0,1,0,0,-3.3,0,GO:0002532,production of molecular mediator involved in inflammatory response,M010,1,0
1,0,0,-3.1,0,0,R-HSA-9664420,Killing mechanisms,M100,1,0
0,1,0,0,-3.4,0,WP4205,MET in type 1 papillary renal cell carcinoma,M010,1,0
1,0,0,-3.5,0,0,WP3972,PDGFR beta pathway,M100,1,0
0,0,1,0,0,-3.3,GO:0051607,defense response to virus,M001,1,0
0,1,0,0,-3.4,0,GO:0043434,response to peptide hormone,M010,1,0
0,1,0,0,-5.5,0,GO:1901653,cellular response to peptide,M010,1,0
1,0,0,-2.4,0,0,GO:0048565,digestive tract development,M100,1,0
1,0,0,-2.2,0,0,CORUM:643,CtBP core complex,M100,1,0
0,1,0,0,-3.4,0,hsa05231,Choline metabolism in cancer,M010,1,0
0,1,0,0,-3,0,GO:0032645,regulation of granulocyte macrophage colony-stimulating factor production,M010,1,0
0,1,0,0,-2.6,0,GO:1905898,positive regulation of response to endoplasmic reticulum stress,M010,1,0
0,1,0,0,-2.5,0,GO:0032436,positive regulation of proteasomal ubiquitin-dependent protein catabolic process,M010,1,0
0,1,0,0,-2.7,0,M281,PID FAK PATHWAY,M010,1,0
1,0,0,-3.3,0,0,GO:0014013,regulation of gliogenesis,M100,1,0
0,1,0,0,-3.5,0,GO:0071356,cellular response to tumor necrosis factor,M010,1,0
1,0,0,-2.7,0,0,R-HSA-877300,Interferon gamma signaling,M100,1,0
1,0,0,-2.7,0,0,WP1530,miRNA regulation of DNA damage response,M100,1,0
0,1,0,0,-3.3,0,GO:0061919,process utilizing autophagic mechanism,M010,1,0
1,0,0,-2.8,0,0,GO:0062009,secondary palate development,M100,1,0
1,0,0,-2.5,0,0,GO:0045654,positive regulation of megakaryocyte differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0022604,regulation of cell morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-2,0,0,WP4941,GPR143 in melanocytes and retinal pigment epithelium cells,M100,1,0
1,0,0,-2.2,0,0,GO:0010922,positive regulation of phosphatase activity,M100,1,0
0,1,0,0,-2.4,0,GO:0043304,regulation of mast cell degranulation,M010,1,0
0,1,0,0,-2.1,0,GO:1903320,regulation of protein modification by small protein conjugation or removal,M010,1,0
1,0,0,-2.5,0,0,GO:0002286,T cell activation involved in immune response,M100,1,0
1,0,0,-5.3,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M100,1,0
1,0,0,-2.3,0,0,WP4949,16p11 2 proximal deletion syndrome,M100,1,0
0,1,0,0,-3,0,GO:1903305,regulation of regulated secretory pathway,M010,1,0
0,1,0,0,-3.5,0,R-HSA-76002,"Platelet activation, signaling and aggregation",M010,1,0
0,1,0,0,-2.5,0,hsa04014,Ras signaling pathway,M010,1,0
0,1,0,0,-2.4,0,GO:0046456,icosanoid biosynthetic process,M010,1,0
1,0,0,-2.9,0,0,GO:0062207,regulation of pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0060322,head development,M100,1,0
0,0,1,0,0,-2.2,GO:0050679,positive regulation of epithelial cell proliferation,M001,1,0
1,0,0,-3.7,0,0,GO:0048514,blood vessel morphogenesis,M100,1,0
1,0,0,-5,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-2.4,0,0,R-HSA-2029485,Role of phospholipids in phagocytosis,M100,1,0
1,0,0,-2.5,0,0,GO:0032814,regulation of natural killer cell activation,M100,1,0
1,0,0,-2.8,0,0,R-HSA-9006335,Signaling by Erythropoietin,M100,1,0
1,0,0,-2.5,0,0,GO:1990858,cellular response to lectin,M100,1,0
1,0,0,-2.2,0,0,GO:0043153,entrainment of circadian clock by photoperiod,M100,1,0
1,0,0,-2.1,0,0,WP4756,Renin angiotensin aldosterone system RAAS,M100,1,0
0,1,0,0,-3.4,0,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M010,1,0
0,1,0,0,-2.1,0,R-HSA-2559585,Oncogene Induced Senescence,M010,1,0
1,0,0,-2.6,0,0,R-HSA-391160,Signal regulatory protein family interactions,M100,1,0
1,0,0,-2.4,0,0,GO:0036293,response to decreased oxygen levels,M100,1,0
1,0,0,-2,0,0,GO:1901222,regulation of non-canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2.8,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
1,0,0,-3.5,0,0,GO:0007405,neuroblast proliferation,M100,1,0
0,1,0,0,-2.4,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M010,1,0
0,1,0,0,-3.2,0,GO:0006911,"phagocytosis, engulfment",M010,1,0
0,1,0,0,-2.4,0,GO:0051101,regulation of DNA binding,M010,1,0
1,0,0,-2.4,0,0,GO:0001837,epithelial to mesenchymal transition,M100,1,0
0,1,0,0,-2.2,0,GO:0072595,maintenance of protein localization in organelle,M010,1,0
1,0,0,-2.5,0,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0040007,growth,M100,1,0
1,0,0,-2.4,0,0,GO:0001825,blastocyst formation,M100,1,0
0,1,0,0,-3.7,0,R-HSA-109582,Hemostasis,M010,1,0
1,0,0,-3.7,0,0,GO:0001944,vasculature development,M100,1,0
0,1,0,0,-2.3,0,GO:0032755,positive regulation of interleukin-6 production,M010,1,0
1,0,0,-2.2,0,0,hsa04670,Leukocyte transendothelial migration,M100,1,0
0,1,0,0,-3.5,0,R-HSA-9013148,CDC42 GTPase cycle,M010,1,0
1,0,0,-4.9,0,0,GO:0072091,regulation of stem cell proliferation,M100,1,0
0,1,0,0,-2.4,0,GO:1902903,regulation of supramolecular fiber organization,M010,1,0
0,1,0,0,-3.8,0,GO:0007264,small GTPase mediated signal transduction,M010,1,0
1,0,0,-2,0,0,GO:0007369,gastrulation,M100,1,0
1,0,0,-2,0,0,R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,M100,1,0
1,0,0,-4.6,0,0,R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,M100,1,0
0,1,0,0,-2.5,0,GO:0002931,response to ischemia,M010,1,0
1,0,0,-2.8,0,0,M274,PID LYMPH ANGIOGENESIS PATHWAY,M100,1,0
1,0,0,-2.5,0,0,GO:0002068,glandular epithelial cell development,M100,1,0
1,0,0,-2.3,0,0,GO:0001838,embryonic epithelial tube formation,M100,1,0
0,1,0,0,-2.6,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M010,1,0
0,1,0,0,-5.3,0,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M010,1,0
0,1,0,0,-2.5,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M010,1,0
1,0,0,-3,0,0,M23,PID WNT NONCANONICAL PATHWAY,M100,1,0
0,1,0,0,-3.4,0,hsa05152,Tuberculosis,M010,1,0
0,1,0,0,-2.6,0,GO:0009267,cellular response to starvation,M010,1,0
1,0,0,-4,0,0,GO:0003002,regionalization,M100,1,0
1,0,0,-2.6,0,0,GO:0048706,embryonic skeletal system development,M100,1,0
0,1,0,0,-2.3,0,GO:2001242,regulation of intrinsic apoptotic signaling pathway,M010,1,0
0,1,0,0,-2.9,0,GO:0032656,regulation of interleukin-13 production,M010,1,0
0,1,0,0,-2.5,0,GO:0060348,bone development,M010,1,0
0,1,0,0,-2.2,0,GO:1901800,positive regulation of proteasomal protein catabolic process,M010,1,0
1,0,0,-2.2,0,0,GO:0032720,negative regulation of tumor necrosis factor production,M100,1,0
1,0,0,-3.6,0,0,GO:0046632,alpha-beta T cell differentiation,M100,1,0
0,1,0,0,-2.5,0,GO:0030890,positive regulation of B cell proliferation,M010,1,0
0,1,0,0,-3.4,0,GO:0045577,regulation of B cell differentiation,M010,1,0
0,1,0,0,-2.3,0,GO:0015718,monocarboxylic acid transport,M010,1,0
0,1,0,0,-2.7,0,R-HSA-912526,Interleukin receptor SHC signaling,M010,1,0
1,0,0,-2.7,0,0,GO:0071236,cellular response to antibiotic,M100,1,0
0,0,1,0,0,-5.1,R-HSA-8941333,RUNX2 regulates genes involved in differentiation of myeloid cells,M001,1,0
0,1,0,0,-2.2,0,R-HSA-2029481,FCGR activation,M010,1,0
0,1,0,0,-4,0,R-HSA-9664422,FCGR3A-mediated phagocytosis,M010,1,0
1,0,0,-2,0,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M100,1,0
0,1,0,0,-2.6,0,GO:0090630,activation of GTPase activity,M010,1,0
1,0,0,-3.1,0,0,GO:0060333,type II interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0048341,paraxial mesoderm formation,M100,1,0
1,0,0,-2.2,0,0,GO:0010863,positive regulation of phospholipase C activity,M100,1,0
1,0,0,-2.9,0,0,R-HSA-8943724,Regulation of PTEN gene transcription,M100,1,0
1,0,0,-4.1,0,0,WP236,Adipogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0002069,columnar/cuboidal epithelial cell maturation,M100,1,0
0,1,0,0,-3.1,0,R-HSA-202733,Cell surface interactions at the vascular wall,M010,1,0
0,1,0,0,-2.7,0,WP185,Integrin mediated cell adhesion,M010,1,0
1,0,0,-4.5,0,0,GO:0032703,negative regulation of interleukin-2 production,M100,1,0
1,0,0,-2.4,0,0,GO:0034121,regulation of toll-like receptor signaling pathway,M100,1,0
1,0,0,-4.1,0,0,GO:0002718,regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-2.6,0,0,GO:0034154,toll-like receptor 7 signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M36,PID IL27 PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0043583,ear development,M100,1,0
0,1,0,0,-2.6,0,R-HSA-5687128,MAPK6/MAPK4 signaling,M010,1,0
1,0,0,-2.3,0,0,GO:0002292,T cell differentiation involved in immune response,M100,1,0
0,1,0,0,-2,0,GO:0032434,regulation of proteasomal ubiquitin-dependent protein catabolic process,M010,1,0
1,0,0,-6.3,0,0,M290,PID IL12 STAT4 PATHWAY,M100,1,0
1,0,0,-3.4,0,0,GO:0009855,determination of bilateral symmetry,M100,1,0
1,0,0,-2.6,0,0,GO:0044790,suppression of viral release by host,M100,1,0
1,0,0,-2.5,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
0,1,0,0,-2.1,0,GO:0045620,negative regulation of lymphocyte differentiation,M010,1,0
0,1,0,0,-3.8,0,GO:0050871,positive regulation of B cell activation,M010,1,0
1,0,0,-3.2,0,0,GO:0060760,positive regulation of response to cytokine stimulus,M100,1,0
0,1,0,0,-2.9,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M010,1,0
0,1,0,0,-4.5,0,WP2877,Vitamin D receptor pathway,M010,1,0
1,0,0,-2.3,0,0,GO:0062208,positive regulation of pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-3.8,0,0,WP3527,Pre implantation embryo,M100,1,0
1,0,0,-3.2,0,0,GO:0071695,anatomical structure maturation,M100,1,0
0,1,0,0,-2.5,0,R-HSA-76009,Platelet Aggregation (Plug Formation),M010,1,0
1,0,0,-2.5,0,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M100,1,0
1,0,0,-2,0,0,M241,PID RAC1 REG PATHWAY,M100,1,0
1,0,0,-5.4,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M100,1,0
1,0,0,-5,0,0,GO:0002237,response to molecule of bacterial origin,M100,1,0
0,1,0,0,-2,0,hsa03320,PPAR signaling pathway,M010,1,0
0,1,0,0,-2.7,0,GO:1902236,negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,M010,1,0
1,0,0,-3.1,0,0,M213,PID AR NONGENOMIC PATHWAY,M100,1,0
0,1,0,0,-3.1,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M010,1,0
0,1,0,0,-3.1,0,GO:0099024,plasma membrane invagination,M010,1,0
1,0,0,-3.1,0,0,GO:0060759,regulation of response to cytokine stimulus,M100,1,0
1,0,0,-3.1,0,0,GO:0002071,glandular epithelial cell maturation,M100,1,0
1,0,0,-2.2,0,0,hsa05165,Human papillomavirus infection,M100,1,0
0,1,0,0,-2.1,0,GO:0043123,positive regulation of canonical NF-kappaB signal transduction,M010,1,0
1,0,0,-2.2,0,0,M30,PID HDAC CLASSII PATHWAY,M100,1,0
